

Appendix

Dr. Leonid Margolis

Bibliography

Invited oral presentations

Multiple oral presentations at National and International Meetings, including Keystone symposia, International Microbicide Conferences, International AIDS Conferences etc.

Monograph

Margolis, L.B., Bergelson, L.D. Liposomes and their Interactions with Cells. 1986. 320 printed pages ("Science" Publ. House, Moscow).

Main publications in peer-reviewed journals

1. Margolis, L.B. (1970). Synchronization of processes in cell cycle. *Cytology*. 12: 122
2. Vasiliev, Ju.M., Gelfand, I.M., Margolis, L.B., Samoilov, V.I. (1971) Quantitative evaluation of cellular form and orientation. *Ontogenesis*, 2: 46
3. Domnina, L.V., Ivanova, O. Yu., Margolis, L.B., Vasiliev, Yu. M., Gelfand, I.M. (1972).
Defective formation of the lamella cytoplasm by neoplastic fibroblasts. *Proc. Natl. Acad. Sci USA*. 69,1:248
4. Vasiliev, Ju.M., Margolis, L.B., Domnina, O.Yu., Ivanova, O.Yu., Komm, S.G. (1973) Cell-cell interactions in cultures of transformed L fibroblasts and normal cells. *Cytology*, 15: 1213
5. Gelstein, V.I., Ivanova, O.Yu., Domnina L.V., Margolis, L.B., Pletushkina, O.Yu., Vasiliev, Yu. M., Gelfand, I.M. (1973) Contact inhibition of movement in the cultures of transformed cells. *Proc. Natl. Acad. Sci. USA*. 70:2341

6. Bershadsky, A.D., Gelstein, V.I., Domnina, L.V., Ivanova, O.Yu., Margolis, L.B., Vasiliev, Yu. M., Gelfand, I.M. (1973). Interactions of normal and neoplastic cells with various surfaces. *Neoplasma*. 20:386
7. Ivanova, O. Yu., Margolis, L.B.(1973) Use of phospholipid film for shaping cell cultures. *Nature*. 242:200.
8. Vasiliev, Ju.M., Gelfand, I.M., Margolis, L.B., Samoilo, V.I. (1974) A method of determining mitotic furrow in cultured cells. *Ontogenesis*, 6,1:105.
9. Ivanova, O.Yu., Margolis, L.B., Vasiliev, Yu. M., Gelfand, I.M. (1974). Orientation of mitotic furrow is determined in interphase. *Proc. Natl. Acad. Sci. USA*. 71:2003.
10. Vasiliev, Ju.M., Gelfand, I.M., Margolis, L.B. (1975) Orientation of cell mitotic furrow. *Proc. of Acad. Sci. USSR*. 214,3:685.
11. Petrovskaya, M.B., Margolis, L.B., Leontovich, A.M., Vasiliev, N.B., Pjatetsky-Shapiro, I. (1975) Computer simulation of establishing cell orientation by means of local interactions between cells. *Ontogenesis*, 4.
12. Margolis, L.B., Samoilo, V.I., Vasilev, Yu. M., Gelfand, I.M. (1975). Quantitative evaluation of cell orientation. *J. Cell Sci*. 17:243:1.
13. Margolis, L.B., Bergelson, L.D. (1975). Introduction of cytostatics into the cells with the help of liposomes as a method to overcome drug resistance. *Proc. Acad. Sci. USSR*. 225:941.
14. Ivanova, O. Yu., Margolis, L.B., Gelfand, I.M. (1976). Effect of colcemid on the spreading of fibroblasts in culture. *Exp. Cell Res*. 101:207.
15. Margolis, L.B., Dorfman, N.A. (1977). Immunospecific liposomes. *Proc. Soc. Exper. Biol. Med*. 87:53.
16. Ivanova, O. Yu., Margolis, L.B., Gelfand, I.M., Komm, S.G. (1977). Effect of colcemid on cell polarization on narrow strands of adhesive substrate. *Cytology*, 29,3: 357.
17. Margolis, L.B., Dzatlovitskaya, E.V., Bergelson, L.D. (1978). Cell-lipid interactions. Cell attachment to lipid substrates. *Exp. Cell Res*. 111:454.
18. Dzatlovitskaya, E.V., Bergelson, L.D., Margolis, L.B. (1978). Study of cell adhesion to lipid films of various composition. *Proc. Acad. Sci. USSR* 239,5:1226.
19. Margolis, L.B., Bergelson, L.D. (1979). Lipid-cell interactions. Induction of microvilli on the cell surface. *Exp. Cell Res*. 119:145.
20. Margolis, L.B., Vasiliev, Yu. M., Gelfand, I.M. (1979). Upper surface of epithelial sheets and of fluid lipid films are unadhesive for platelets. *Proc. Natl. Acad. Sci. USA* 76:2303.

21. Margolis, L.B., Tikhonov, A.N., Vasilieva, E. Yu. (1980). Platelet adhesion to fluid and solid phospholipid membranes. *Cell* 19:1996.
22. Baibakov, B.A., Bergelson, L.B., Margolis, L.B. (1980) Lipid exchange between cells and liposomes. *Proc. Acad. Sci. USSR* 254,5:1265.
23. Neifakh, A.A., Vasiliev, Ju.M., Bergelson, L.D., Margolis, L.B. (1980) Interaction of fluid and solid liposomes with various parts of epithelial cell surface. *Proc. Acad. Sci. USSR* 225,6:1479.
24. Margolis, L.B. (1981) liposomes and cells: membrane interactions. In: *Liposomes* (L.D.Bergelson, ed.) Medicine Publ., Moscow.
25. Margolis, L.B., Victorov, A.V., Bergelson, L.D. (1982). Lipid-cell interactions. A novel mechanism of transfer of liposome-entrapped substances into the cells. *Biochim. Biophys. Acta* 720:259.
26. Margolis, L.B., Neifakh, A.A., Vasiliev, Yu. M., Bergelson, L.D. (1982). Interaction of solid liposomes with epithelial sheets. *Cell Biol. Intern. Rep.* 6:131.
27. Margolis, L.B., Neifakh, A.A. (1982). Cell interactions with liposomes, part 1, Liposomes with lipid-crystalline membranes. *Adv. Modern Biol.* 93:(2)214.
28. Margolis, L.B., Neifakh, A.A. (1982). Cell interactions with liposomes, part 2, Liposomes with gel-phase membranes, proteoliposomes. *Adv. Modern Biol.* 93:(4)83.
29. Baibakov, B.A., Bergelson, L.D., Margolis, L.B., Victorov, A.V. (1982) Liposome contact lysis: new mechanism of liposome delivery into cells. *Proc. Acad. Sci. USSR* 264,5:1253.
30. Margolis, L.B., Neifakh A.A. (1983) Distribution of solid liposomes on the surface of epithelial sheet. *Cytology* 25,6:690.
31. Margolis, L.B., Neyfakh., A.A. (1983). The distribution of solid liposomes of different size on time surface of epithelial cells. *Eur. J. Cell Biol.* 25:256.
32. Margolis, L.B., Namiot, V.A., Kljukin, L.M. (1983). Magnetoliposomes: another principle of the cell sorting. *Biochim. Biophys. Acta* 735:193.
33. Margolis, L.B., Neifakh, A.A. (1983). Liposomes inhibit intercellular attachment. *Exp. Cell Res.* 148:536.
34. Margolis, L.B., Bergelson, L.D. (1983). Use of liposomes in modelling cell-cell interactions. In: *Liposome Letters*. (A. Bangham ed.) Academic Press, p. 395.
35. Margolis, L.B., Baibakov, B.A., Neifakh, A.A., Viktorov, A.V., Galkina, S.I., Bergelson, L.D. (1984). Lipid-cell-interactions, Liposome adsorption and cell-to-liposomes lipid transfer are mediated by the same cell surface sites. *Biochim. Biophys. Acta.* 804:23.

36. Margolis, L.B. (1984). Cell interactions with model membranes: probing modification and simulation of cell membranes. *Biochim. Biophys. Acta* (Reviews on Biomembranes) 779:161.
37. Margolis, L.B., Neifakh, A.A. (1984) Inhibition of cell aggregation by liposomes. *Proc. Acad. Sci. USSR* 274,6:1470
38. Margolis, L.B., Sharovskaja Ju.Ju. (1985) formation of cell-cell permeable contacts and morphological alterations in epithelial cell cultures. *Proc. Acad. Sci. USSR* 281,1:233.
39. Margolis, L.B. (1985). Lipid membranes as an instrument for studying cell surface. Trends in Science & Technology. (Yuri Chismadjev ed.), Moscow.
40. Margolis, L.B., Baibakov, B.A., Galkina, S.I., Molotkovsky, Yu. G., Neifakh, A.A., Bergelson, L.D. (1985). Competition between "solid" and fluid liposomes for binding to the cell surface. *Cytology* 27,9:1021.
41. Bogdanov, A.A., Gordeeva, L.V., Margolis, L.B., Torchilin, V.P. (1986). Concanavalin A immobilized on the liposome surface. Binding to normal and transformed cells. *Biol. Membr.* 3:674.
42. Margolis, L.B., Gordeeva, L.V. (1986) Interaction of epithelial cells with the edges of "solid" and "fluid" lipid films. *Cytology* 28:699.
43. Sharovskaya, Yu. Yu., Margolis, L.B., Snegirevskaya, E.S., Komissarchik, Ya. Yu., Chailakhjan, L.M. (1987). Induction of cell-cell communication in cell cultures. *Biol. Membr.* 4:298.
44. Margolis, L.B., Popov, S.V. (1987). Induction of cell process by mechanical force locally applied to cell membrane. *Biol. Membr.* 4,1:26
45. Sharovskaja, Yu., Chailakhjan, L.M., Margolis, L.B. (1988). Induction of intercellular communications in epithelial cell cultures. *Exp. Cell Res.* 175,2:404.
46. Margolis, L.B. (1988). Cell interactions with solid and fluid liposomes in vitro: lessons for "Liposomologists" and cell biologists. In: Liposome for Drug Targeting: Trends and Progress (G. Gregoriadis ed.) John Wiley & Sons, p.75.
47. Gordeeva, L.V., Bogdanov, A.A., Baibakov, B.A., Torchilin, V.P., Margolis, L.B. (1988). Adhesion defect of ascites cel corrected with membrane-bound attachment molecules. *FEBS Lett.* 124:185.
48. Gordeeva, L.V., Bogdanov, V.P., Torchilin, V.P., Margolis, L.B. (1988). Interaction of con-A-liposomes with cells: binding to normal and transformed mouse fibroblasts. In: Liposome for Drug Targeting: Trends and Progress. (G. Gregoriadis ed.) John Wiley & Sons, p. 421.
49. Margolis, L.B., Rozovskaja, Cragoe E. (1988). Intracellular pH and cell adhesion to the substrate. *FEBS Lett.* 234:449.

50. Popov, S.I., Margolis, L.B. (1988). Formation of cell outgrowths by external force: a model study. *J. Cell Sci.* 90:379.
51. Margolis, L.B., Rozovskaya, I.A., Novikova, I.P., Skulachev, V.P. (1989). K/H-antiporter nigericin arrests DNA synthesis in Ehrlich ascite carcinoma cells. *Proc. Natl. Acad. Sci. USA* 86:6629.
52. Margolis, L.B., Popov, S.V. (1988). Generation of cell processes in high frequency electric field. *Bioelectrochemistry and Bioenergetics* 20:143.
53. Margolis, L.B. (1989). Cell interactions with model membranes. *Sci. Rev. D. Physiochemical Biol. Harwood Acad. Publ.* 9:143.
54. Bogdanov, A.A., Gordeeva, L.V., Torchilin, V.P., Margolis, L.B. (1989). Lectin-bearing liposomes: Differential binding to normal and transformed mouse fibroblasts. *Exp. Cell Res.* 4181:362.
55. Margolis, L.B., Rozovskaya, I.A., Skulachev, V.P. (1990). Nigericin as a factor decreasing intracellular pH and inhibiting DNA synthesis in Ehrlich ascite carcinoma. *Biol. Membr.* 3:1863.
56. Baibakov, B.A., Glaser, D., Margolis, L.B. (1990). Influence of cytocholasin D on the lipid transfer between cells and liposomes. *Biochem. Biomed. Acta* 49:129.
57. Margolis, L.B., Popov, S.V. (1990). Induction of cell processes in electric field. *Biol. Membr.s* (in Russian) 7:514.
58. Margolis, L.B., Novikova, I.Yu., Rozovskaya, I.A., Skulachev, V.P. (1990) *Probl. Oncol.* 36, 8:952.
59. Gass, G.A., Chernomordik, L.V., Margolis, L.B. (1991). Local deformation of human red blood cells in high frequency electric field. *Biochim. Biophys. Acta* 1093:162.
60. Budunova, I.A., Mittleman, L.A., Margolis, L.B. (1991). An upward shift of intracellular pH rather than the final absolute pH value is critical for controlling gap junction permeability in tumor promotro-treated cells. *FEBS Lett.* 279:52.
61. Margolis, L.B., Popov, S.V. (1991). Induction of cell process by local force. *J. Cell Sci.* 98:369.
62. Li, L., Margolis, L.B., Hoffman, R.M. (1991). Measurement of multicell-type skin toxicity in three-dimensional in vitro native-state histoculture. *Proc. Natl. Acad. Sci. USA* 88:1908.
63. Bogdanov, A.A., Gordeeva, L.V., Baibakov, B.A., Torchilin, V.P., Margolis, L.B. (1991). Restoration of adhesive potentials of Ehrlich ascites carcinoma cells by modification of plasma membrane. *J. Cell Physiol.* 147:182.
64. Popov, S.I., Svitkina, T.M., Margolis L.B. (1991). Mechanism of cell protrusion formation in electrical field: the role of actin. *Biochim. Biophys. Acta* 1066:151.

65. Galkina, S.I., Ivanov, V.V., Preobrazensky, S.N., Bergelson, L.D., Margolis, L.B. (1991). Low-density lipoproteins interact with liposome-binding sites on the cell surface. *FEBS Lett.* 287:19.
66. Li, L., Margolis, L.B., Hoffman, R.M., (1991). Native-state sponge-gel histoculture of intact three dimensional tissue for in vitro toxicity assays. In : "In vitro toxicology: mechanisms and new technology", A.M Goldberg, editor, Mary Ann Libert Inc. Publ., New York.
67. Mittleman, L.A., Budunova, I.V., Muravjeva, O.V. and Margolis, L.B. (1991). Cytoplasmic pH and activator of protein kinase C as co-factors in regulation of gap junction permeability. *Biol. Membr.* (Russian) 8,11:854.
68. Galkina S.I., Sud'ina, G.F., and Margolis, L.B. (1991). Intercellular contacts and intercellular signalling. *Biol. Membr.* (Russian) 8:1151.
69. Glushakova, S.E., Ksenofontov, A.L., Fedorov, N.V., Mazul, L.A., Ageeva, O.N., Margolis, L.B., Baratova, L.A., Shishkov, A.V. (1991) A model for study of the mechanism of low pH-induced interaction of the virus fusion proteins and cell membranes. *Biosci. Rep.* 11:131.
70. Galkina, S.I., Baibakov, B.A., Budunova, I.V., Muravjeva, O., Margolis, L.B. (1992) Cell-substratum interactions: adhesion, spreading and intracellular signalling in mammalian cells. *Biofouling* 5:195.
71. Galkina, G., Sud'ina, G., Margolis, L. (1992). Cell-cell contacts alter intracellular pH. *Exper. Cell Res.* 200:211.
72. Baibakov, G., Frank, G., Sergeeva, N., Novikova, T., Yongkin, T., Connors, K, Hoffman, R, Margolis, L. (1992). In vivo growth pattern of human lung tumors in three-dimensional histoculture. *In Vitro Cell Dev. Biol.* 27A:897.
73. Margolis, L. (1992). Does American science need Russian Humanitarian Aid? *New Biologist* 4:413.
74. Li, L., Margolis, L., Paus, R., Hoffman, R. (1992). Hair shaft elongation, follicle growth, and spontaneous regression in long-term, gelatin sponge-supported histoculture of human scalp skin. *Proc. Natl. Acad. Sci. USA* 89:8764.
75. Li, L., Margolis, L., Hoffman, R. (1992). In vitro hair growth from histocultured mouse skin. *In Vitro Cell Dev. Biol.* 28:479.
76. Li, L., Margolis, L., Lishko, V., Hoffman, R. (1992). Product-delivering liposomes specially target hair follicles in histocultured intact skin. *In Vitro Cell Dev. Biol.* 28:679.
77. Dunina-Barkovskaja, A., Muravjeva, O., Margolis, L. (1993). Intracellular pH and buffering power of mouse hepatocytes. *Biol. Memb.* (Russian), 10:14.

78. Galkina, S.I., Sud'ina, G.F., Margolis, L.B. (1993) Effect of cell interactions on stimulation of neutrophils and fibroblasts. The role of intracellular pH. *Biol. Memb.* (Russian), 10, 1:20.
79. Galkina, S.I., Sud'ina, G.F., Margolis, L.B. (1993) Intercellular contacts affect stimulation of neutrophils and fibroblasts: the role of intracellular pH. *Biol. Memb.* (Russian), 7:17.
80. B.A.Baibakov, G.A.Frank, L.B.Margolis, V.P.Skulachev (1993) Anti-tumor effect of K⁺/H⁺ -antiporter nigericin on human lung carcinoma grown in in vivo-like histocultures. *Int. J. Oncol.*, 3:1127.
81. G.F.Sud'ina, S.I.Galkina, O.A.Barsky, Margolis, L.B. (1993) Adhesive interactions of neutrophils and leucotriene synthesis. *FEBS Lett.*, 336,2 :201.
82. Margolis, L.B. (1993). Cell Interaction with Liposomes in: *Liquid-Crystalline and Gel-Phase State. Liposomes in Ophthalmology and Dermatology*. Edited by U.Pleyer, K.Schmidt and H.J. Thiel. Hippokrates Verlag Stuttgart. p.13.
83. Novikova, I.Yu., Muravyeva, O.V., Cragoe, E.J., Margolis, L.B. (1994) Study of fibroblast spreading: pH-dependence, involvement of Na/H-antiporter and PKC. *Biochim Biophys Acta*, 1178, 267.
83. Muravjova, O.V., Dunina-Barkovskaya, A.Y., Margolis, L.B. (1994) Intracellular pH and in intercellular junctional conductance. *Biol.Membr.*, 10:527.
85. Tairbekov, M.G., Margolis, L.B., Baibakov, B.A., Gabova A.V., Dergacheva, G.B. (1994) Growth and motility of cells in culture in microgravity conditions (experiment "Fibroblasts"). *Ann. 9 100. 101. Russian Academy Sci. (Biological series)*, 5:745-750.
86. B.A Baibabkov, T.A.Chipisheva, V.I.Guelstein, V.D.Ermilova, E.B.Polevaya, J.M.Vasiliev, L.B. Margolis (1994) Organotypic growth and differentiation of human mammary gland in sponge-gel matrix supported hystoculture. *In Vitro Cell Dev. Biol.*, 30, 490-495.
87. D.F.Huelser, G.Zempel, B.Reuss, D.Suhr, Yu.Yu.Sharovskaya, O.V.Muravjova, A.Yu.Dunina-Barkovskaya, L.B.Margolis (1994) Arachidonic acid reversibly reduces intercellular junction permeability. *Biol. Membr.* 11, 50-55.
88. L.B.Margolis, S.E. Glushakova, B.A. Baibakov, C.Collin and J.Zimmerberg (1995). The behavior of individual tumor cells within cultured tissue blocks:anisotropic locomotion. *In Vitro Cell Dev. Biol.*, 31, 221-225.
89. L.B.Margolis, B.A. Baibakov, C.Collin and S.Simon (1995). Dye coupling in three dimensional histocultures of rat lingual epithelia. *In Vitro Cell Dev. Biol.*, 31, 456-461.
90. S.I Galkina G.F.Sud'ina, G.B.Dergavheva, LB.Margolis (1995). Regulation of intracellular pH by cell-cell adhesive interactions. *FEBS Lett.*, 374:17-20.

91. L.B.Margolis, S.E. Glushakova, B.A. Baibakov, J.Zimmerberg (1995). Syncytium formation in cultured human lymphoid tissue: fusion of implanted HIV gp120/41-expressing cells with native CD4+ cells. *AIDS Res. Hum. Retrov.*, 11, 697-704.
92. S. Hatfill, L.B. Margolis and P. Durray (1996). In viro maintenance of normal and pathological human salivary gland tissue in NASA-designed rotating wall vessel bioreactor. *Cell Vision*, 3, 397-401.
- 93 S. Glushakova, B.Baibakov, L.B.Margolis (corresp. author), and J.Zimmerberg (1996). Infection of tonsil histocultures: a model for HIV pathogenesis. *Nature Med.*, 1:1320-1322.
94. S.I. Galkina, G.F. Sud'ina, and L.B.Margolis (1996). Regulation of intracellular pH by phospholipase A 2 and protein kinase c upon neutrophil adhesion to solid substrata. *FEBS Lett.*, 393:117-120.
95. S.Glushakova, B.Baibakov, J.Zimmerberg and L.B.Margolis (1997). Experimental HIV infection of human lymphoid tissue. Correlation of CD4+ T cell depletion in and virus syncytium-inducing/non-syncytium inducing phenotype in histocultures inoculated with laboratory strains and patient isolates of HIV-1. *AIDS Res. Hum. Retrov.*, 13, 461-471.
- 96 L.B.Margolis, W.Fitzgerald, S.Glushakova, S.Hatfill, N.Amichai, B.Baibakov, J.Zimmerberg (1997). Lymphocyte trafficking and HIV infection of human lymphoid tissue in rotating wall vessel bioreactor. *AIDS Res. Hum. Retrov.*, 13:1411-20.
97. G.Sud'ina, S.Galkina. L.B.Margolis, V. Ulrich (1998). Dependence of neutrophil activation on cell density and adhesion. *Cell Adhesion Comm.*, 5,27-37.
98. J.Hwang, L.B. Margolis, M.Edidin (1998) Domains in cell plasma membraness investigated by near-field optical microscopy. *J.Biophys.*, 74, 2184-90.
99. L.B. Margolis, S. Glushakova, J.-C. Grivel, P. Murphy (1998). Blockade of CCR5-tropic HIV-1 replication in human lymphoid tissue by CC chemokines. *J.Clin. Inv.*, 101, 1876-80.
100. S. Glushakova, J.-C. Grivel, W. Fitzgerald, J. Zimmerberg, L. B. Margolis (1998). Evidence for the HIV-1 phenotype switch as a causal factor in aquired immunodeficiency. *Nature Med.*, 4, 346-349.
- L.B.Margolis (1998). HIV: from molecular recognition to tissue pathogenesis. (A review). *FEBS Lett.*, 433, 5-8.
102. A. Sylwester, J.C.Grivel, W. Fitzgerald, J.Rossio, J .Lifson, L.B. Margolis (1998). CD4+ lymphocyte depletion in human lymphoid tissue ex vivo is not induced by non-infectious HIV-1 virions. *J. Virol.*, 72, 9345-9347.
103. M. Penn, J-C. Grivel, B. Schramm, M. Goldsmith, L.B. Margolis (1999). CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1 infected human lymphoid tissue. *Proc.Natl. Acad. Sci. USA*, 96, 663-668.

104. L. Margolis, S. Hatfill, R. Chuaqui, K. Vocke, M. Emmert-Buck, P. Duray (1999). Long term organ culture of human prostate tissue in NASA designed rotating wall vessel bioreactor. *J. Urol.*, 161, 290-297.
105. J.-C. Grivel, L.B. Margolis (1999). CCR5-tropic HIV-1 isolates are highly cytopathic but only for CCR5+/CD4+ T cells in human lymphoid tissue ex vivo. *Nature Med.*, 5, 344-346.
106. S. Glushakova, J.-C. Grivel, K. Suryarayana, J. Lifson, P. Meylan, R. Desrosiers, L.B. Margolis (1999). Nef enhances HIV-1 replication and responsiveness to IL-2 in human lymphoid tissue ex vivo. *J. Virol.*, 73, 3968-3974.
107. L.B. Margolis, J.-C. Grivel (1999). Cytokine modulation of HIV-1 chemokine receptor expression. (Letter to the Editor) *Nature Med.*, 5, 6, 592-593
108. S. Glushakova, Y. Yi, J.-Ch Grivel, A. Singh, D. Schols, E. De Clercq, R. G. Collman, L. Margolis (1999) Preferential usage of CCR5 or CXCR4 co-receptors by dual-tropic HIV-1 in human lymphoid tissue ex vivo: Consequences for cytopathicity. *J. Clin Inv.* 104, R7-R11. (See comments *J. Clin Inv.* 104, 531-532).
109. A. Bleuvelt, S. Glushakova, L. Margolis (2000). Langerhans cells transmit HIV-1 infection to human lymphoid tissue ex vivo. *AIDS*, 14, 647-651.
110. J.-C. Grivel, M. Penn, B. Schramm, R. Speck, B. Herndier, L. Margolis (corresponding author) and M. Goldsmith (2000) HIV-1 coreceptor preferences determine target T-cell depletion in human lymphoid tissue. *Proc. Natl. Acad. Sci. USA* 96, 663-668.
111. J.-C. Grivel, N. Malkevich and L. Margolis (2000). Infection of human lymphoid tissue by CXCR-4-utilizing HIV-1 induces apoptosis in CD4+ but not in CD8+ T lymphocytes *J. Virology* 74, 17, 8077-8084.
112. L. Margolis, S. Glushakova, C. Chougnat, G. Shearer, P. Markham, M. Robert-Guroff, R. Benveniste, C. J. Miller, V. Hirsch, M. Cranage, and G. Franchini (2000). Susceptibility of rhesus macaques' lymph nodes ex vivo to simian immunodeficiency virus predicts infectiveness of rhesus macaques following mucosal exposure. *Virology*, 275, 391-397.
113. T. Kawamura, S.S. Cohen, D. Borris, E. Aquilino, S. Glushakova, L. Margolis, J. Orenstein, R. Offord, A. Neurath and Andrew Blauvelt (2000) Candidate Microbicides Block HIV-1 Infection of Human Immature Langerhans Cells within Epithelial Tissue Explants *J. Exp. Med.* 192: 1491-1500.
114. N. Malkevitch, D. McDermott, Y. Yi, J.-C. Grivel, D. Schols, E. De Clercq, P. M. Murphy, S. Glushakova, R. Collman and L. Margolis (2001). Coreceptor choice and T cell depletion by R5, X4 and R5X4 HIV-1 variants in CCR5-deficient (CCR5 Δ 32) and normal human lymphoid tissue. *Virology* 281, 239-247.
115. N. Malkevich, N. C. Womack, A. Fauci, L. Margolis (2001) Human Immunodeficiency Virus Type 1 (HIV-1) Non-B Subtypes Are Similar to HIV-1 Subtype B in that Coreceptor Specificity Is a Determinant of Cytopathicity in Human Lymphoid Tissue Infected Ex Vivo. *J. Virol* 75, 10520-10522.

116. S. Glushakova, J. Muench, S. Carl, T. Greenborough, J. Sullivan, L. Margolis (corresp. author), F. Kirchhoff (2001) CD4 down-modulation by human immunodeficiency virus type 1 nef correlates with the efficiency of viral replication and with CD4(+) T- cell depletion in human lymphoid tissue ex vivo. *J. Virol.* 75, 10113-10117.
117. J-C. Grivel, S.Santoro, G. Faga, M. Malnati, Y. Ito, W. Fitzgerald, P. Lusso, L. Margolis (2002) Suppression of CCR5- but not CXCR4-tropic HIV-1 replication in lymphoid tissue by human herpesvirus 6. *Nature Medicine* 1223-1235.
118. F. Gondois-Rey, J-C. Grivel, A.Biancotto, M. Pion, R. Vigne, L. Margolis (corresponding author), I. Hirsch. (2002) Segregation of R5 and X4 HIV-1 variants to memory T cell subsets differentially expressing CD62L in ex vivo infected human lymphoid tissue. *AIDS* 16, 1245-1249.
119. S. Papini, D. Cecchetti, D. Campani, W. Fitzgerald, J-Ch. Grivel, S. Chen, L. Margolis, R. Revoltella (2003) Isolation and clonal analysis of human epidermal keratinocyte stem cells in long-term culture. *Stem Cells* 21:481-494.
120. J-Ch. Grivel, A. Biancotto, Y. Ito, R. Gomes, L.B. Margolis (2003) Bystander CD4 T lymphocytes survive in HIV-infected human lymphoid tissue. *AIDS Research and Human Retrov.* 19, 3, 211-216.
121. S. Chen, R. P. Revoltella, S. Papini, M. Michelini, W. Fitzgerald, J. Zimmerberg and L. Margolis (2003) Multi-lineage Differentiation of Rhesus Monkey Embryonic Stem Cells in Three-Dimensional Culture Systems. *Stem Cells* 21, 281-295.
122. Y. Ito, J.-Ch. Grivel, and L. Margolis (2003) Real-Time PCR Assay of Individual Human Immunodeficiency Virus Type 1 Variants in Coinfected Human Lymphoid Tissues. *J. Clin. Microbiol.* 41, 2126-2131.
123. L. Margolis (2003) Chemokines: strategic weapons in germ warfare: Microbes as antimicrobials *Nature Biotechnology* 21, 1 15-16.
124. J.-Ch. Grivel, F. Santoro, S. Chen, G. Fagá, M. S. Malnati, Y. Ito, L. Margolis (corresponding author) and P. Lusso (2003) Pathogenic effects of human herpesvirus 6 in human lymphoid tissue ex vivo *J. Virol.* 77: 8280-8289.
125. Y. Ito, J-Ch. Grivel, S. Chen, Y. Kiselyeva, P. Reichelderfer and L. Margolis (2004) CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines *J. Infect. Dis.* 189: 506-514.
126. J. Kwik, S. Boyle, D. Fooksman, L Margolis, M. Sheetz, M. Edidin (2004) Membrane cholesterol, lateral mobility and the P(4,5)P2-dependnet organization of cell actin. *Proc Natl. Acad. Sci. USA* 100: 13964-9.
127. W. Fitzgerald, A. Sylwester, J-Ch. Grivel, J. Lifson, and L. Margolis (2004) Non-infectious X4 but not R5 HIV-1 virions inhibit immune responses in human lymphoid tissue ex vivo *J. Virol J. Virol* 78, 13:7061-68.

128. A. Biancotto, J-Ch. Grivel, F. Gondois-Rey, L. Bettendroffer, R. Vigne, S. Brown, L. Margolis, and I. Hirsch (2004) Dual role of prostratin in inhibition of infection and reactivation of latency of human immunodeficiency virus in primary blood lymphocytes and in lymphoid tissue. *J. Virol.* 78: 10507-15
129. E. Rücker, J-C. Grivel, J. Münch, F. Kirchhoff and L. Margolis (2004) Vpr and Vpu are important for efficient HIV-1 replication and CD4+ T cell depletion in human lymphoid tissue *ex vivo*. *J. Virol* 78: 12689-93.
130. E.Rücker, J. Münch, S. Wildum, M. Brenner, J. Eisemann, L. Margolis and F.Kirchhoff A (2004) Naturally occurring variation in the proline-rich region does not attenuate human immunodeficiency virus type 1 Nef function *J. Virol* 78, 18 10197-201
131. Kiselyeva Y, Ito I, Lima RD, Grivel J-C, Das AT, Berkhout B, Margolis L. (2004) Depletion of CD4 T lymphocytes in human lymphoid tissue infected *ex vivo* with doxycycline-dependent HIV-1. *Virology* 328, 1, 1-6.
132. P. Duray, S-R. Yin, Y. Ito, L. Bezrukov, C. Cox, M-S. Cho, W. Fitzgerald, D. Dorward, J.. Zimmerberg, and L. Margolis (2005) Invasion of human tissue *ex vivo* by *Borrelia burgdorferi*. *J. Infect. Dis.* 191, 1747-54 (See also the Journal cover)
133. D. Philp, W. Fitzgerald, S. Chen, J. Orenstein, H. K. Kleinman, L. Margolis (2005) Complex extracellular matrices promote tissue-specific stem cell differentiation. *Stem Cells* 23(2):288-96.
134. S. Chen R. Revoltella, J.Zimmerberg, and L. Margolis (2005), "Differentiation of rhesus monkey embryonic stem cells in Collagen gel". *Embryonic Stem Cell II: Protocols and Methods*.
135. D. Philp, Chen SS, Fitzgerald W, Orenstein J, Margolis L, Kleinman HK (2005) Complex extracellular matrices promote tissue-specific stem cell differentiation. *Stem Cells*. 23:288-96.
136. P. Fletcher, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R (2005) The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. *J Virol.* 79:11179-86.
137. J-Ch. Grivel, M. Garcia, B. Moss and L. Margolis (2005) Measles virus inhibits HIV replication in human lymphoid issue *ex vivo* *J. Infect. Dis.* 192, 71-8.
138. I. Karlsson, J-C. Grivel, S. Chen, A. Karlsson, J. Albert, EM. Fenyö and L. Margolis. (2005) Differential pathogenesis of primary CCR5-using HIV-1 isolates in human lymphoid tissue *ex vivo*. *J. Virology* 79,11151-60.
139. M Alfano, J-C. Grivel, A. Ciolli, G. Poli, and L. Margolis (2005) The Binding Subunit of Pertussis Toxin Uncouples T Cell Activation from HIV-1 Replication in Lymphoid Tissue *AIDS* 19, 1007-14.

140. Michelini M., Franceschini V, Chen S., Papini S, Rosellini A, Ciani F, Margolis L, Revoltella R. Primate embryonic stem cells create their own *niche* while differentiating in three-dimensional culture systems. *Cell Prolif* 2006; 39, 217-229.
- 141 Chen S, Revoltella R, Zimmerberg J, Margolis L. Differentiation of rhesus monkey embryonic stem cells in three-dimensional collagen matrix. *Methods Mol Biol* 2006; 330, 431-443.
- 142 Fletcher, P., Elliott, J., Grivel, J-C., Margolis, L, Anton, P., McGowan, I., Shattock, R. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. *AIDS* 2006; 20, 1237-1245.
143. Grivel, J.C., Garcia, M., Moss, W.J. and Margolis, L.B. (2005) Inhibition of HIV-1 replication in human lymphoid tissues ex vivo by measles virus. *J Infect Dis*, 192, 71-78.
144. Karlsson, I., Grivel, J.C., Chen, S.S., Karlsson, A., Albert, J., Fenyo, E.M. and Margolis, L. (2005) Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. *J Virol*, 79, 11151-11160.
145. Philp, D., Chen, S.S., Fitzgerald, W., Orenstein, J., Margolis, L. and Kleinman, H.K. (2005) Complex extracellular matrices promote tissue-specific stem cell differentiation. *Stem Cells*, 23, 288-296.
146. Chen, S.S., Revoltella, R.P., Zimmerberg, J. and Margolis, L. (2006) Differentiation of rhesus monkey embryonic stem cells in three-dimensional collagen matrix. *Methods Mol Biol*, 330, 431-443.
147. Fletcher, P.S., Elliott, J., Grivel, J.C., Margolis, L., Anton, P., McGowan, I. and Shattock, R.J. (2006) Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. *Aids*, 20, 1237-1245.
148. Margolis, L. and Shattock, R. (2006) Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? *Nat Rev Microbiol*, 4, 312-317.
149. Michelini, M., Franceschini, V., Sihui Chen, S., Papini, S., Rosellini, A., Ciani, F., Margolis, L. and Revoltella, R.P. (2006) Primate embryonic stem cells create their own niche while differentiating in three-dimensional culture systems. *Cell Prolif*, 39, 217-229.
150. Biancotto, A., Grivel, J.C., Iglehart, S.J., Vanpouille, C., Lisco, A., Sieg, S.F., Debernardo, R., Garate, K., Rodriguez, B., Margolis, L. Lederman, M.L. (2007) Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. *Blood*, 109, 4272-4279.
151. Chen, S.S., Fitzgerald, W., Zimmerberg, J., Kleinman, H.K. and Margolis, L. (2007) Cell-cell and cell-extracellular matrix interactions regulate embryonic stem cell differentiation. *Stem Cells*, 25, 553-561.

152. Condack, C., Grivel, J.C., Devaux, P., Margolis, L. and Cattaneo, R. (2007) Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration. *J Infect Dis*, 196, 541-549.
- 153 Grivel, J.C., Elliott, J., Lisco, A., Biancotto, A., Condack, C., Shattock, R.J., McGowan, I., Margolis, L. and Anton, P. (2007) HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. *Aids*, 21, 1263-1272.
154. Kiselyeva, Y., Nedellec, R., Ramos, A., Pastore, C., Margolis, L. and Mosier, D.E. (2007) Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations. *J Virol*, 81, 3657-3661.
155. Lisco, A., Grivel, J.C., Biancotto, A., Vanpouille, C., Origgi, F., Malnati, M.S., Schols, D., Lusso, P. and Margolis, L. (2007) Viral interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. *J Virol*, 81, 708-717.
156. Munch, J., Rucker, E., Standker, L., Adermann, K., Goffinet, C., Schindler, M., Wildum, S., Chinnadurai, R., Rajan, D., Specht, A., Giménez-Gallego, G., Sánchez, P., Fowler, D.M., Koulov, A., Kelly, J.W., Mothes, W., Grivel, J-C., Margolis, L., Keppler, T., Forssmann, W-G., Kirchhoff, F. (2007) Semen-derived amyloid fibrils drastically enhance HIV infection. *Cell*, 131, 1059-1071.
157. van Laar, J.M., Melchers, M., Teng, Y.K., van der Zouwen, B., Mohammadi, R., Fischer, R., Margolis, L., Fitzgerald, W., Grivel, J.C. *et al.* (2007) Sustained secretion of immunoglobulin by long-lived human tonsil plasma cells. *Am J Pathol*, 171, 917-927.
158. Vanpouille, C., Biancotto, A., Lisco, A. Brichacek, Margolis L. (2007) Interactions between human immunodeficiency virus type 1 and vaccinia virus in human lymphoid tissue ex vivo. *J Virol*, 81, 12458-12464.
159. Vermeire, K., Lisco, A., Grivel, J.C., Scarbrough, E., Dey, K., Duffy, N., Margolis, L., Bell, T.W. and Schols, D. (2007) Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity. *Biochem Pharmacol*, 74, 566-578.
160. Biancotto, A., Iglehart, S.J., Lisco, A., Vanpouille, C., Grivel, J.C., Lurain, N.S., Reichelderfer, P.S. and Margolis, L.B. (2008) Upregulation of human cytomegalovirus by HIV type 1 in human lymphoid tissue ex vivo. *AIDS Res Hum Retroviruses*, 24, 453-462.
161. Biancotto, A., Iglehart, S.J., Vanpouille, C., Condack, C.E., Lisco, A., Ruecker, E., Hirsch, I., Margolis, L.B. and Grivel, J.C. (2008) HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. *Blood*, 111, 699-704.
162. Fichorova, R.N., Richardson-Harman, N., Alfano, M., Belec, L., Carbonneil, C., Chen, S., Cosentino, L., Curtis, K., Dezzutti, C.S., Donoval, B. Doncel, G. F., Donaghay, M., Grivel, J. C, Guzman, E., Hayes, M., Herold, B., Hillier, S., Lackman-Smith, C., Landay, A., Margolis, L. *et al.* (2008) Biological and technical variables affecting immunoassay recovery

of cytokines from human serum and simulated vaginal fluid: a multicenter study. *Anal Chem*, 80, 4741-4751.

163. Lederman, M.M. and Margolis, L. (2008) The lymph node in HIV pathogenesis. *Semin Immunol*, 20, 187-195.

164. Lisco, A., Vanpouille, C., Tchesnokov, E.P., Grivel, J.C., Biancotto, A., Brichacek, B., Elliott, J., Fromentin, E., Shattock, R., Anton, P., Gorelick, R., Balzarini, J., McGuigan, C., Derudas, M., Gotte, M., Schinazi, R. F., Margolis, L. (2008) Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. *Cell Host Microbe*, 4, 260-270.

165. Fichorova RN, Richardson-Harman N, Alfano M, Belec L, Carbonneil C, Chen S, Cosentino L, Curtis K, Dezzutti CS, Donoval B, Doncel GF, Donaghay M, Grivel JC, Guzman E, Hayes M, Herold B, Hillier S, Lackman-Smith C, Landay A, Margolis L, Mayer KH, Pasicznyk JM, Pallansch-Cokonis M, Poli G, Reichelderfer P, Margolis, L., et al. (2008) Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. *Anal Chem* 80:4741-51.

166. Grivel, J.C., and Margolis, L. (2009) Culture of human tissue explants to study human infectious agents. *Nature Prot*, Nat Protoc 4:256-69.

167. L Lisco A, Vanpouille C, Margolis L (2009) Coinfecting viruses as determinants of HIV disease. *Curr HIV/AIDS Rep* 6:5-12.

168. C. Vanpouille, Lisco A, Margolis L.B. (2009) Off-label indication: acyclovir as an anti-HIV drug. *Future Virology* 4:1-5.

169. W. Fitzgerald, Chen, S., Walz, C Zimmerberg. J., Margolis, L., Grivel, J-C. (2009) Immune suppression of human lymphoid tissues and cells in rotating suspension culture and onboard the international space station. *In Vitro Cell Dev Biol Anim*,

170. A. Biancotto, Brichacek, B., Chen, S., Fitzgerald, W., Lisco, A., Vanpouille, C., Margolis, L., Grivel, J-C. (2009) A highly sensitive and dynamic immunofluorescent cytometric bead assay for the detection of HIV-1 p24. *Viol. Meth.* 157:98-101.

171. A. Sassi, Brichacek, B., Hieny, S., Yarovinsky, F., Golding, H., Grivel, J-C., Sher, A., Margolis, L. (2009) *Toxoplasma gondii* inhibits R5 HIV-1 replication in human lymphoid tissues *ex vivo*. *Microbes Infect.*, 11, 14-15, 1106-13

172. A. Biancotto, Grivel, J-C., Lisco, A., Vanpouille, C., Markham, P.D., Gallo, R., Margolis, L., Lusso, P. (2009) Evolution of SIV toward RANTES resistance in macaques rapidly progressing to AIDS upon coinfection with HHV-6A. *Retrovirology* 6:61.

173. N. Richardson-Harman, Lackman-Smith, C, Fletcher PS, Anton P, Bremer JW, Dezzutti CS, Elliott J, Guenther P, Grivel J, Gupta P, Jones M, Lurain NS, Margolis LB, Richardson-Harman N, Mohan S, Ratner D, Reichelderfer P, Roberts P, Shattock R, Cummins JE (2009) Multi-site comparison of anti-HIV microbicide activity in explant assays using a novel endpoint analysis. *J. Clin. Microbiol.*, 47, 11, 3530-9

174. SR. Iyer, Yu D, Biancotto A, Margolis LB, Wu Y (2009) Measurement of human immunodeficiency virus type 1 preintegration transcription by using Rev-dependent Rev-CEM cells reveals a sizable transcribing DNA population comparable to that from proviral templates. *J Virol* 83:8662-73.
175. EP.Tchesnokov, Obikhod A, Massud I, Lisco A, Vanpouille C, Brichacek B, Balzarini J, McGuigan C, Derudas M, Margolis L, Schinazi RF, Gotte M (2009) Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Mutation in Reverse Transcriptase. *J Biol Chem* 284:21496-504.
176. H. Boukari, Brichacek B, Stratton P, Mahoney SF, Lifson JD, Margolis L, Nossal R (2009) Movements of HIV-Virions in Human Cervical Mucus. *Biomacromolecules*,
177. M. Derudas, Carta D, Brancale A, Vanpouille C, Lisco A, Margolis L, Balzarini J, McGuigan C (2009) The Application of Phosphoramidate ProTide Technology to Acyclovir Confers Anti-HIV Inhibition. *J Med Chem*,
- 178 JK.Lim, Lisco A, McDermott DH, Huynh L, Ward LM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, Follmann D, Margolis LB, Murphy P, Stramer SL (2009) Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. *PLoS Pathog.*;5(2)
- 179 .A. Lisco, Margolis L. Integrating integrins into HIV pathogenesis. *Blood*. 2009 5;113(6):1207-8
181. A.Lisco, Vanpouille C, Margolis L. (2009) A missed point in deciphering the viral synergy between herpes simplex virus and HIV. *Lancet Infect Dis*, 9(9):522-3.
182. N. Richardson-Harman N, Lackman-Smith C, Fletcher PS, Anton PA, Bremer JW, Dezzutti CS, Elliott J, Grivel JC, Guenther P, Gupta P, Jones M, Lurain NS, Margolis L, Mohan S, Ratner D, Reichelderfer P, Roberts P, Shattock RJ, Cummins JE Jr. (2009). Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. *J Clin Microbiol*. 47(11):3530-9.
183. A. Lisco A, Vanpouille C, Margolis L. (2009) War and peace between microbes: HIV-1 interactions with coinfecting viruses. *Cell Host Microbe*.6(5):403-8.
184. C.Vanpouille, Lisco A, Margolis LB (2010) Acyclovir: a new use for an old drug. *Curr Opin Infect Dis*. *Curr Opin Infect Dis*. 22(6):583-7.
185. C.Vanpouille, Lisco A, Derudas M, Saba E, Grivel JC, Brichacek B, Scrimieri F, Schinazi R, Schols D, McGuigan C, Balzarini J, Margolis L. (2010). A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. *J Infect Dis*. 201(4):635-43.
186. E. Saba, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, (corresponding author)Lisco A (2010) HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. *Mucosal Immunol*. 3: 280-90.

187. B. Brichacek, Vanpouille, C, Kiselyeva Y, Biancotto, A Merbah, Hirsch, I, Lisco A, Grivel J-C, Margolis L. Contrasting Roles for TLR Ligands in HIV-1 *Pathogenesis* (2010). 20 Sep 2010 doi:10.1371/journal.pone.0012831.
188. JC. Grivel, Shattock RJ, Margolis LB (2011) Selective transmission of R5 HIV-1 variants: where is the gatekeeper? *Journal of Translational Medicine* 9 (Suppl 1):S6 .
189. M. Merbah, Introini, A., Fitzgerald W. Grivel, J-C, Lisco, A., Vanpouille C., Margolis LB (2011) Cervico-Vaginal Tissue *Ex Vivo* as a Model to Study Early Events in HIV-1 Infection *American J. Reprod. Immunol.*65, 3, 268–278.
190. E.J. Ciccone, Greenwald, J H., Lee, P I., Biancotto, A, Read, S.W., Yao, M.A., Hodge, J N., Thompson, W L., Kovacs, S B., Chairez, C L., Migueles, S A., Kovacs, J A., Margolis, L B. Sereti, I. (2011). CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. *J Virol.*85, 588–8.
191. A. Lisco, Munawwar A, Introini A, Vanpouille C, Saba E, Feng X, Grivel J, Singh S, Margolis LB. (2011) HIV-1 and reactivated coinfecting herpesviruses reprogram the cytokine network in semen of infected individuals. *J Infect Dis* 2011 . 10.1093/infdis/jir700.
192. A.Graciela A, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, Cihlar T, Perno C, Snoeck R, Margolis L. (corresponding author), Balzarini J. (2011) Topical tenofovir as dual-targeted anti-human immunodeficiency virus and anti-herpesvirus microbicide. *Cell Host Microbes.* 10(4): 379–389.
193. Grivel JC, Ivanova O, Pinegina N, Blank PS, Shpektor A, Margolis L. (corresponding author), and Vasileva E. (2011) Activation of T lymphocytes in atherosclerotic plaques. *Arteriosclerosis, Thrombosis and Vascular Biology.* 31 (12): 2929-37.
194. Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, Cihlar T, Perno C, Snoeck R, Margolis LB (corresponding author), Balzarini J. (2011) Topical tenofovir as dual-targeted anti-human immunodeficiency virus and anti-herpesvirus microbicide. *Cell Host&Microbe.* 10:1-11.
195. Vanpouille C., Arakelyan A., Margolis, L (2012). Microbicides: still a long road to success. *Trends in Microbiology.* 8:369-35.
196. Lisco A.,Munawwar, Introini A, Vanpouille V, Saba E, Feng X, Grivel J-C, Singh S and Margolis L (2012). "Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network." *The Journal of Infectious Diseases* 205(1): 97-105.
197. Vanpouille C, Lisco A, Introini A Grivel J-C, Munawwar A., Merbah M., Schinazi RF, Derudas M, McGuigan C, Balzarini J, Margolis L. (2012). Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin. *Antimicrobial Agents and Chemotherapy* 56(5): 2604-2611.
198. Lisco A., Introini, A, Munawwar,A. Vanpouille C, Grivel J-C, Blank, P, Singh,S, Margolis, L. (2012) HIV-1 imposes rigidity on blood and semen cytokine networks. *American J. Reproductive Immunol.* 68 (5), 515–521.

199. Introini, A, Vanpouille, C, Lisco A, Grivel, J-C, Margolis, L. (2013). Interleukin-7 Facilitates HIV-1 Transmission to Cervico-Vaginal Tissue *ex vivo*. *PLoS Pathogen*;9:1-10.
200. Saba E, Origoni M, Taccagni G, Ferrari, D, Doglioni C, Nava A, Lisco A, Grivel J-C, Margolis L. (corresponding author), Poli G.(2013) Productive HIV-1 infection of human cervical tissue *ex vivo* is associated with the secretory phase of the menstrual cycle. *Mucosal Immunol*;6(6):1081-90.
201. Arakelyan A, Fitzgerald W, Margolis L (corr. auth), Grivel J-C. (2013) Flow virometry: a nanoparticle based technology for analysis of individual viral particles. *J Clin Invest* 123:3716-3727.
202. McGuigan C, Bourdin C, Derudas M, Hamon N, Hinsinger K, Kandil S, Madela K, Meneghesso S, Pertusati F, Serpi M, Slusarczyk M, Chamberlain S, Kolykhalov A, Vernachio J, Vanpouille C, Introini A, Margolis L, Balzarini J.(2013) Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. *Eur J Med Chem* 2013;70:326-40.
203. Arakelyan A, Fitzgerald W, Grivel JC, Vanpouille C, Margolis L. (2014) Histocultures (tissue explants) in human retrovirology. *Methods Mol Biol* 2014;1087:233-48.
204. Barreto-de-Souza V, Arakelyan A, Margolis L. (corresponding author), Vanpouille C. HIV-1 vaginal transmission: cell-free or cell-associated virus? (2014). *Am J Reprod Immunol* 71:589-99.
205. Introini A, Vanpouille C, Grivel J, Margolis LB. (2014). An *ex vivo* Model of HIV-1 Infection in Human Lymphoid Tissue and Cervico-vaginal Tissue. *Bio-protocols*;4:4-19.
206. Vanpouille C, Khandzhinskaya A, Karpenko I, Zicari S, Barreto-de-Souza V, Frolova S, Margolis L. (corresponding author), Kochetkov S. (2014) A new antiviral: Chimeric 3TC-AZT phosphonate efficiently inhibits HIV-1 in human tissues *ex vivo*. *Antiviral Res* 109:125-31.
207. Arakelyan A, Ivanova O, Vasileva E, Grivel J-C, Margolis L. (2014). Antigenic composition of single nano-sized extra-cellular vesicles. *Nanomedicine*; 11(3):489-498. 2015. PMID: 25481806.
208. Matyugina ES, Novikov MS, Babkov DA, Valuev-Elliston VT, Vanpouille C*, Zicari S*, Corona a, Tramontano E, Margolis L*, Khandzhinskaya AL, Kochetkov SN. 5-Arylaminoouracil Derivatives as Potential Dual-Action Agents. *Acta Naturae*; 7(3):113-115. 2015. PMCID: PMC4610172.
209. Romero R, Grivel JC*, Tarca AL, Chaemsaitong P, Xu Z, Fitzgerald W*, Hassan SS, Chaiworapongsa T, Margolis L*. Evidence of perturbations of the cytokine network in preterm labor. *Am J Obstet Gynecol*; 213(6):e831-836. 2015. PMCID: PMC4679519.
210. Gianella S, Smith DM, Daar ES, Dube MP, Lisco A*, Vanpouille C*, Margolis L*, Haubrich RH, Morris SR. Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men. *PLoS One*; 10(6):e0130410. 2015. PMCID: MC4465639.

211. Vanpouille C*, Lisco A*, Grivel JC*, Bassit LC, Kauffman RC, Sanchez J, Schinazi RF, Lederman MM, Rodriguez B, Margolis L*. Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial. *Clin Infect Dis*; 60(11):1708-1714. 2015. PMID: PMC4447783.

#This paper was accompanied by the NIH press release and was cited in mass media

212. Margolis L*. Immunoactivation at the crossroads of human disease. *Am J Med* 2015; 128(6):562-566. 2015. PMID: PMC4517936.

213. Nikitskaya E, Lebedeva A, Ivanova O, Maryukhnich E, Shpektor A, Grivel JC*, Margolis L*, Vasilieva E. Cytomegalovirus-Productive Infection Is Associated With Acute Coronary Syndrome. *J Am Heart Assoc*; 5(8). 2016. PMID: PMC5015295.

214. Knickelbein JE, Liu B, Arakelyan A*, Zicari S*, Hannes S, Chen P, Li Z, Grivel JC*, Chaigne-Delalande B, Sen HN, Margolis L*, Nussenblatt RB. Modulation of Immune Responses by Extracellular Vesicles From Retinal Pigment Epithelium. *Invest Ophthalmol Vis Sci*; 57(10):4101-4107. 2016. PMID: PMC4991022.

215. Nikitskaya EA, Grivel JC*, Maryukhnich EV, Lebedeva AM, Ivanova OI, Savvinova PP, Shpektor AV, Margolis L*, Vasilieva EY. Cytomegalovirus in Plasma of Acute Coronary Syndrome Patients. *Acta Naturae* 2016; 8(2):102-107. PMID: PMC4947993.

216. Nolte-'t Hoen E, Cremer T, Gallo RC, Margolis L*. Extracellular vesicles and viruses: Are they close relatives? *Proc Natl Acad Sci U S A*; 113(33):9155-9161. 2016. PMID: PMC4995926.

217. Vagida MS, Arakelyan A*, Lebedeva AM, Grivel JC*, Shpektor AV, Vasilieva EY, Margolis L*. Analysis of Extracellular Vesicles Using Magnetic Nanoparticles in Blood of Patients with Acute Coronary Syndrome. *Biochemistry*; 81(4):382-391. 2016. PMID: PMC4966537.

218. Shmagel KV, Saidakova EV, Shmagel NG, Korolevskaya LB, Chereshev VA, Robinson J, Grivel JC*, Douek DC, Margolis L*, Anthony DD, Lederman MM. Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection. *HIV Med*; 17(8):581-589. 2016. PMID: PMC4987156.

219. Zicari S*, Arakelyan A*, Fitzgerald W*, Zaitseva E, Chernomordik LV, Margolis L*, et al. Evaluation of the maturation of individual Dengue virions with flow virometry. *Virology*; 488:20-27. 2016. PMID: PMC4744565.

#This paper was selected by the Editors to be highlighted as paper of the months for *Virology* Highlights Blog.

220. Merbah M, Onkar S, Grivel JC*, Vanpouille C*, Biancotto A, Bonar L, Sanders-Buell E, Kijak G, Michael N, Robb M, Kim JH, Tovanabuttra S, Chenine AL. Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes. *J Virol Methods*; 230:45-52. 2016. PMID: 26808359.

221. Vanpouille C*, Introini A*, Morris SR, Margolis L*, Daar ES, Dube MP, Little SJ, Smith DM, Lisco A, Gianella S. Distinct cytokine/chemokine network in semen and blood

characterize different stages of HIV infection. *AIDS*; 30(2):193-201. 2016. PMID: PMC4862605.

222. Vorobyova DA, Lebedev AM, Vagida MS, Ivanova OI, Felker EI, Gontarenko VN, Shpektor AV, Margolis L*, Vasilieva EY. Immunological Analysis of Human Atherosclerotic Plaques in ex vivo Culture System. *Cardiologia*; 56(11):78-85. 2016. PMID: 28290822.

223. Barreto-de-Souza V*, Arakelyan A*, Zicari S*, Margolis L*, Vanpouille C*. Monocytes but Not Lymphocytes Carrying HIV-1 on Their Surface Transmit Infection to Human Tissue Ex Vivo. *J Virol*; 90(21):9833-9840. 2016. PMID: PMC5068533.

224. Arakelyan A*, Fitzgerald W*, Vagida M, Vasilieva E, Margolis L*, Grivel JC*. Addition of thrombin reduces the recovery of extracellular vesicles from blood plasma. *J Circ Biomark*; 5:1849454416663648. 2016. PMID: PMC5548196.

225. Arakelyan A*, Fitzgerald W*, Zicari S*, Vagida M, Grivel JC*, Margolis L*. Flow Virometry to Analyze Antigenic Spectra of Virions and Extracellular Vesicles. *J Vis Exp*; (119). 2017. PMID: PMC5308558.

226. Shmagel KV, Korolevskaya LB, Saidakova EV, Shmagel NG, Chereshnev VA, Margolis L*, Anthony D, Lederman, M. HCV coinfection of the HIV-infected patients with discordant CD4+ T-cell response to antiretroviral therapy leads to intense systemic inflammation. *Dokl Biol Sci*. 477(1):244-247. 2017. PMID: 29299802.

227. Vanpouille C*, Bernatchez JA, Lisco A, Arakelyan A*, Saba E, Gotte M, Margolis L*. A common anti-cytomegalovirus drug, ganciclovir, inhibits HIV-1 replication in human tissues ex vivo. *AIDS*; 31(11):1519-1528. 2017. PMID: PMC5541768.

228. Tarca AL, Fitzgerald W*, Chaemsaitong P, Xu Z, Hassan SS, Grivel JC*, Gomez-Lopez N, Panaitescu B, Pacora P, Maymom E, Erez O, Margolis L* (corr auth), Romero R. The cytokine network in women with an asymptomatic short cervix and the risk of preterm delivery. *Am J Reprod Immunol*; 78(3). 2017. PMID: PMC5575567.

229. Nahui Palomino RA, Zicari S, Vanpouille C, Vitali B, Margolis L. Vaginal Lactobacillus Inhibits HIV-1 Replication in Human Tissues Ex Vivo. *Front Microbiol*; 8:906. 2017. PMID: PMC5437121

230. Arakelyan A, Fitzgerald W, King DF, Rogers P, Cheeseman HM, Grivel JC, Shattock RJ, Margolis L. Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. *Sci Rep*; 7(1):948. 2017. PMID: PMC5430429.

231. Arakelyan A, Fitzgerald W, Zicari S, Vanpouille C, Margolis L. Extracellular Vesicles Carry HIV Env and Facilitate HIV Infection of Human Lymphoid Tissue. *Sci Rep*; 7(1):1695. 2017. PMID: PMC5431974 .

#This paper was accompanied by the NIH press release, was cited in mass media and was chosen by the AIDS Rev as "hot news".

232. Kaur S, Elkahloun AG, Singh SP, Arakelyan A*, Roberts DD. A function-blocking CD47 antibody modulates extracellular vesicle-mediated intercellular signaling between breast carcinoma cells and endothelial cells. *J Cell Commun Signal*; 2017. PMID: 29188480.
233. Introini A, Vanpouille C*, Broliden K, Margolis L*. Ex vivo infection of human lymphoid tissue and female genital mucosa with human immunodeficiency virus 1 and histoculture. *J Vis Exp*; 2017.
234. Lebedeva A, Vorobyeva D, Vagida M, Ivanova O, Felker E, Fitzgerald W*, Danilova N, Gontarenko V, Shpektor A, Vasilieva E, Margolis L*. Ex vivo culture of human atherosclerotic plaques: A model to study immune cells in atherogenesis. *Atherosclerosis*; 267:90-98. 2017. PMID: 29101840.
235. Alexandrova L, Zicari S, Matyugina E, Khandazhinskaya A, Smirnova T, Andreevskaya S, Chernousova L, Vanpouille C, Kochetkov S, Margolis L. Dual-targeted anti-TB/anti-HIV heterodimers. *Antiviral Res.* 2017 Sep;145:175-183. doi: 10.1016/j.antiviral.2017.07.011. Epub 2017 Jul 22. PMID: 28743447.
236. Christensen-Quick A, Vanpouille C*, Lisco A, Gianella S. Cytomegalovirus and HIV Persistence: Pouring Gas on the Fire. *AIDS Res Hum Retroviruses*; 33(S1):S23-S30. 2017. PMID: PMC5684659.
237. Chaillon A, Smith DM, Vanpouille C*, Lisco A, Jordan P, Caballero G, Vargas M, Gianella S, Mehta SR. HIV Trafficking Between Blood and Semen During Early Untreated HIV Infection. *J Acquir Immune Defic Syndr*; 74(1):95-102. 2017. PMID: PMC5140710.
238. Derudas M, Vanpouille C, Carta D, Zicari S, Andrei G, Snoeck R, Brancale A, Margolis L, Balzarini J, McGuigan C. Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. *J Med Chem*; 60(18):7876-7896. 2017. PMID: PMC5731253.
239. Alexandrova L, Zicari S, Matyugina E, Khandazhinskaya A, Smirnova T, Andreevskaya S, Chernousova L, Vanpouille C, Kochetkov S, Margolis L. Dual-targeted anti-TB/anti-HIV heterodimers. *Antiviral Res*; 145:175-183. 2017. PMID: PMC5576140.
240. Vagida M, Arakelyan A, Lebedeva A, Grivel JC, Shpektor A, Vasilieva E, Margolis L. Flow analysis of individual blood extracellular vesicles in acute coronary syndrome. *Platelets*; 28(2):165-173. 2017. PMID: PMC5811196.
241. Zaitseva E, Zaitsev E, Melikov K, Arakelyan A, Marin M, Villasmil R, Margolis L, Melikyan GB, Chernomordik LV. Fusion Stage of HIV-1 Entry Depends on Virus-Induced Cell Surface Exposure of Phosphatidylserine. *Cell Host Microbe*; 22(1):99-110 e117. 2017. PMID: PMC5558241.
242. Kaur S, Elkahloun AG, Arakelyan A*, Young L, Myers TG, Otaizo-Carrasquero F, Wu W, Margolis L (corr auth), Roberts DD. CD63, MHC class 1, and CD47 identify subsets of extracellular vesicles containing distinct populations of noncoding RNAs. *Sci Rep*; 8(1):2577; 2018. PMID: 29416092.

243. Zicari S, Arakelyan A, Palomino RAÑ, Fitzgerald W, Vanpouille C, Lebedeva A, Schmitt A, Bomsel M, Britt W, Margolis L. Human cytomegalovirus-infected cells release extracellular vesicles that carry viral surface proteins. *L. Virology*. 2018 Nov;524:97-105. doi: 10.1016/j.virol.2018.08.008. Epub 2018 Aug 27. PMID: 30165311.
244. Introini A, Vanpouille C, Fitzgerald W, Broliden K, Margolis L. Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture. *J Vis Exp*. 2018 Oct 12;(140):57013. doi: 10.3791/57013. PMID: 30371673.
245. Fitzgerald W, Gomez-Lopez N, Erez O, Romero R, Margolis L. Extracellular vesicles generated by placental tissues ex vivo: A transport system for immune mediators and growth factors. *Am J Reprod Immunol*. 2018 Jul;80(1):e12860. doi: 10.1111/aji.12860. Epub 2018 May 4. PMID: 29726582.
246. Fitzgerald W, Freeman ML, Lederman MM, Vasilieva E, Romero R, Margolis L. A System of Cytokines Encapsulated in ExtraCellular Vesicles. *Sci Rep*. 2018 Jun 12;8(1):8973. doi: 10.1038/s41598-018-27190-x. PMID: 29895824.
247. Introini A, Fitzgerald W, Vanpouille C, Margolis L. Histoculture and Infection with HIV of Functional Human Lymphoid Tissue. *Methods Mol Biol*. 2018;1760:187-197. doi: 10.1007/978-1-4939-7745-1_17. PMID: 29572804.
248. Nahui P, Vanpouille C, Laghi L, Parolin C, Melikov K, Backlund P, Vitali B, Margolis L. Extracellular vesicles from symbiotic vaginal lactobacilli inhibit HIV-1 infection of human tissues. *Nat Commun*. 2019 Dec 11;10(1):5656. doi: 10.1038/s41467-019-13468-9. PMID: 31827089.
249. Arakelyan A, Petersen D, Blazkova J, Margolis L. Macrophage-derived HIV-1 carries bioactive TGF-beta. *Sci Rep* 2019 Dec 13;9(1):19100. doi: 10.1038/s41598-019-55615-8.
250. Lisco A, Wong CS, Price S, Ye P, Niemela J, Anderson M, Richards E, Manion M, Mystakelis H, Similuk M, Lo B, Stoddard J, Rosenzweig S, Vanpouille C*, Rupert A., Maric I, Perez-Diez A, Parenti D, Burbelo PD, Rao VK, Sereti I. 2019b. Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS). *Front Immunol* 10, 1193. PMID: 31191551; PMCID: PMC6549489
251. Margolis L*, Sadovsky Y. 2019. The biology of extracellular vesicles: The known unknowns. *PLoS Biol* 17, e3000363. PMID: 31318874; PMCID: PMC6667152
252. Nahui Palomino RA*, Vanpouille C*, Laghi L, Parolin C, Melikov K, Backlund P, Vitali B, Margolis L*. 2019. Extracellular vesicles from symbiotic vaginal lactobacilli inhibit HIV-1 infection of human tissues. *Nat Commun* 10, 5656. PMID: 31827089 PMCID: PMC6906448
253. Uygur B, Melikov K, Arakelyan A*, Margolis L*, Chernomordik LV. 2019. Syncytin 1 dependent horizontal transfer of marker genes from retrovirally transduced cells. *Sci Rep* 9, 17637. PMID: 31776415; PMCID: PMC6881383
254. Bhatti G, Romero R, Rice GE, Fitzgerald W*, Pacora P, Gomez-Lopez N, Kavdia M, Tarca AL, Margolis L*. 2020. Compartmentalized profiling of amniotic fluid cytokines in

women with preterm labor. *PLoS One* 15, e0227881. PMID: 31945128 PMCID: PMC6964819

255.Chen B, Morris SR, Panigrahi S, Michaelson GM, Wyrick JM, Komissarov AA, Potashnikova D, 255.Lebedeva A*, Younes SA, Harth K, Kashyap VS, Vasilieva E, Margolis L*, Zidar DA, Sieg SF, Shive CL, Funderburg NT, Gianella S, Lederman MM, Freeman, ML. 2020. Cytomegalovirus Coinfection Is Associated with Increased Vascular-Homing CD57(+) CD4 T Cells in HIV Infection. *J Immunol* 204, 2722-2733. PMID: 32229536; PMCID: PMC7315224

256.Dubrovsky L, Ward A, Choi SH, Pushkarsky T, Brichacek B, Vanpouille C*, Adzhubei AA, Mukhamedova N, Sviridov D, Margolis L*, Jones RB, Miller YI, Bukrinsky M. 2020b. Inhibition of HIV Replication by Apolipoprotein A-I Binding Protein Targeting the Lipid Rafts. *mBio* 11. PMID: 31964734; PMCID: PMC6974568

257.Fitzgerald W*, Freeman ML, Lederman MM, Vasilieva E, Romero R, Margolis L*. 2020. Author Correction: A System of Cytokines Encapsulated in ExtraCellular Vesicles. *Sci Rep* 10, 18935. PMID: 33116271; PMCID: PMC7595038

258.Kalinskaya A, Dukhin O, Molodtsov I, Maltseva A, Sokorev D, Elizarova A, Sapozhnikova O, Glebova K, Stonogina D, Shakhidzhanov S, Nikonov E, Mazus A, Spiridonov I, Ataulkhanov F, Margolis L*, Shpektor A, Vasilieva E. 2020. Dynamics of coagulopathy in patients with different COVID-19 severity. *medRxiv*. PMID: 32637973; PMCID: PMC7340199

259. Lebedeva A*, Fitzgerald W*, Molodtsov I, Shpektor A, Vasilieva E, Margolis L*. 2020a. Differential clusterization of soluble and extracellular vesicle-associated cytokines in myocardial infarction. *Sci Rep* 10, 21114. PMID: 33273611; PMCID: PMC7713058

260.Lebedeva A*, Maryukhnich E, Grivel JC*, Vasilieva E, Margolis L*, Shpektor A. 2020b. Productive Cytomegalovirus Infection Is Associated With Impaired Endothelial Function in ST-Elevation Myocardial Infarction. *Am J Med* 133, 133-142. PMID: 31295440; PMCID: PMC6940528

261.Mercurio V*, Fitzgerald W*, Molodtsov I, Margolis L*. 2020. Persistent Immune Activation in HIV-1-Infected Ex Vivo Model Tissues Subjected to Antiretroviral Therapy: Soluble and Extracellular Vesicle-Associated Cytokines. *J Acquir Immune Defic Syndr* 84, 45-53. PMID: 32032302; PMCID: PMC7241305

262. Panigrahi S, Chen B, Fang M, Potashnikova D, Komissarov AA, Lebedeva A*, Michaelson GM, Wyrick JM, Morris SR, Sieg SF, Paiardini M, Villinger FJ, Harth K, Kashyap VS, Cameron MJ, Cameron CM, Vasilieva E, Margolis L*, Younes SA, Funderburg NT, Zidar DA, Lederman MM, Freeman ML. 2020. CX3CL1 and IL-15 Promote CD8 T cell chemoattraction in HIV and in atherosclerosis. *PLoS Pathog* 16, e1008885. PMID: 32976527; PMCID: PMC7540902

263. Sadovsky Y, Ouyang Y, Powell JS, Li H, Mouillet JF, Morelli AE, Sorkin A, Margolis L*. 2020. Placental small extracellular vesicles: Current questions and investigative opportunities. *Placenta* 102, 34-38. PMID: 33218576; PMCID: PMC7680502

264. Sass D*, Fitzgerald W*, Barb JJ, Kupzyk K, Margolis L*, Saligan L. 2020. An exploratory analysis of extracellular vesicle-associated and soluble cytokines in cancer-related fatigue in men with prostate cancer. *Brain Behav Immun Health* 9, 100140. PMID: 34589888; PMCID: PMC8474622

265. Vanpouille C*, Frick A, Rawlings SA, Hoenigl M, Lisco A, Margolis L*, Gianella, S. 2020. Cytokine Network and Sexual Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. *Clin Infect Dis* 71, 2655-2662. PMID: 31768525; PMCID: PMC7744977
266. Vanpouille C*, Margolis L*. 2020. Immune subversion by HIV: part B. *EMBO J* 39, e107167. PMID: 33438774; PMCID: PMC7737603
267. Costantini PE*, Vanpouille C*, Firrincieli A, Cappelletti M, Margolis L*, Nahui Palomino RA*. 2021. Extracellular Vesicles Generated by Gram-Positive Bacteria Protect Human Tissues Ex Vivo From HIV-1 Infection. *Front Cell Infect Microbiol* 11, 822882. PMID: 35145925; PMCID: PMC8821821
268. Kaur S, Elkahloun AG, Petersen JD, Arakelyan A*, Livak F, Singh SP, Margolis L*, Zimmerberg J, Roberts DD. 2021a. CD63(+) and MHC Class I(+) Subsets of Extracellular Vesicles Produced by Wild-Type and CD47-Deficient Jurkat T Cells Have Divergent Functional Effects on Endothelial Cell Gene Expression. *Biomedicines* 9. PMID: 34829933; PMCID: PMC8615535
269. Kaur S, Saldana AC, Elkahloun AG, Petersen JD, Arakelyan A*, Singh SP, Jenkins LM, Kuo B, Reginauld B, Jordan DG, Tran AD, Wu W, Zimmerberg J, Margolis L*, Roberts DD. 2021b. CD47 interactions with exportin-1 limit the targeting of m(7)G-modified RNAs to extracellular vesicles. *J Cell Commun Signal*. PMID: 34841476; no PMCID yet
270. Khandazhinskaya AL, Mercurio V*, Maslova AA, Nahui Palomino RA*, Novikov MS, Matyugina ES, Paramonova MP, Kukhanova MK, Fedorova NE, Yurlov KI, Kushch AA, Tarasova O, Margolis L* (corr auth), Kochetkov SN, Vanpouille, C*. 2021. Dual-targeted anti-CMV/anti-HIV-1 heterodimers. *Biochimie* 189, 169-180. PMID: 34197866; PMCID: PMC8458242
271. Komissarov A, Potashnikova D, Freeman ML, Gontarenko V, Maytesyan D, Lederman MM, Vasilieva E, Margolis L*. 2021. Driving T cells to human atherosclerotic plaques: CCL3/CCR5 and CX3CL1/CX3CR1 migration axes. *Eur J Immunol* 51, 1857-1859. PMID: 33772780; no PMCID yet
272. Mercurio V, Fitzgerald W, Vanpouille C, Molodtsov I, Margolis L. 2021. Mechanisms of residual immune activation in HIV-1-infected human lymphoid tissue ex vivo. *AIDS* 35, 1179-1190. PMID: 33710022; PMCID: PMC8183484
273. Nahui Palomino RA, Vanpouille C, Costantini PE, Margolis L*. 2021. Microbiota-host communications: Bacterial extracellular vesicles as a common language. *PLoS Pathog* 17, e1009508. PMID: 33984071; PMCID: PMC8118305
274. Ouyang Y, Bagalkot T, Fitzgerald W*, Sadovsky E, Chu T, Martinez-Marchal A, Brieno-Enriquez M, Su EJ, Margolis L*, Sorkin A, Sadovsky Y. 2021. Term Human Placental Trophoblasts Express SARS-CoV-2 Entry Factors ACE2, TMPRSS2, and Furin. *mSphere* 6. PMID: 33853873; PMCID: PMC8546705
275. Sass D*, Saligan L, Fitzgerald W*, Berger AM, Torres I, Barb JJ, Kupzyk K, Margolis L*. 2021. Extracellular vesicle associated and soluble immune marker profiles of psychoneurological symptom clusters in men with prostate cancer: an exploratory study. *Transl Psychiatry* 11, 440. PMID: 34429399; PMCID: PMC8385103
276. Silva de Castro I, Gorini G, Mason R, Gorman J, Bissa M, Rahman MA, Arakelyan A*, Kalisz, I, Whitney S, Becerra-Flores M, Ni E, Peachman K, Trinh HV, Read M, Liu, MH, Van

Ryk D, Paquin-Proulx D, Shubin Z, Tuyishime M, Peele J, Ahmadi MS, Verardi R, Hill J, Beddall M, Nguyen R, Stamos JD, Fujikawa D, Min S, Schifanella L, Vaccari M, Galli V, Doster MN, Liyanage NPM, Sarkis S, Caccuri F, LaBranche C, Montefiori DC, Tomaras GD, Shen X, Rosati M, Felber BK, Pavlakis GN, Venzon DJ, Magnanelli W, Breed M, Kramer J, Keele BF, Eller MA, Cicala C, Arthos J, Ferrari G, Margolis L*, Robert-Guroff M, Kwong PD, Roederer M, Rao M, Cardozo TJ, Franchini G. 2021. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. *iScience* 24, 102047. PMID: 33554060; PMCID: PMC7847973

277. Vanpouille C, Gunaydin G, Jangard M, Clerici M, Margolis L*, Broliden K, Introini A. 2021. The Progestin Medroxyprogesterone Acetate Affects HIV-1 Production in Human Lymphoid Tissue Explants in a Dose-Dependent and Glucocorticoid-like Fashion. *Viruses* 13. PMID: 34835109; PMCID: PMC8621851

278. Varese, A, Dantas E, Paletta A, Fitzgerald W, Di Diego Garcia F, Cabrerizo G, Erra Diaz F, Defelipe LA, Pallares H, Dodes Traian M, Gamarnik A, Geffner J, Remes Lenicov F, Margolis L*, Ceballos, A. 2021. Extracellular acidosis enhances Zika virus infection both in human cells and ex-vivo tissue cultures from female reproductive tract. *Emerg Microbes Infect* 10, 1169-1179. PMID: 34013833; PMCID: PMC8205022

279. Kalinskaya A, Dukhin O, Lebedeva A*, Maryukhnich E, Rusakovich G, Vorobyeva D, Shpektor A, Margolis L*, Vasilieva E. 2022. Circulating Cytokines in Myocardial Infarction Are Associated With Coronary Blood Flow. *Front Immunol* 13, 837642. PMID: 35242141; PMCID: PMC8886043

280. Lebedeva A*, Molodtsov I, Anisimova A, Dukhin O, Fitzgerald W*, Fomina D, Ivanova O, Kalinskaya A, Lysenko M, Maryukhnich E, Misyurina E, Protsenko D, Rosin A, Sapozhnikova O, Shpektor A, Vorobyeva D, Vasilieva E, Margolis L*. 2022. Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy. *Int. J. Mol. Sci.* 23(14), 7937. PMID: 35887283; PMCID: PMC9316906

281. Petersen JD, Lu J, Fitzgerald W*, Zhou F, Blank PS, Matthies D, Zimmerberg J, 2022. Unique Aggregation of Retroviral Particles Pseudotyped with the Delta Variant SARS-CoV-2 Spike Protein. *Viruses* 14, 1024. PMID: 35632764; PMCID: PMC9147488

282. Potashnikova D, Saidova A, Tvorogova A, Anisimova A, Botsina A, Vasilieva E, Margolis L*. 2022. CTLs From Patients with Atherosclerosis Show Elevated Adhesiveness and Distinct Integrin Expression Patterns on 2D Substrates. *Front. Med.* PMID: 35911408; PMCID: PMC9328274

283. Poveda E, Tabernilla A, Fitzgerald W*, Salgado-Barreira A, Grandal M, Perez A, Marino A, Alvarez H, Valcarce N, Gonzalez-Garcia J, Bernardino JI, Gutierrez F, Fujioka H, Crespo M, Ruiz-Mateos E, Margolis L*, Lederman MM, Freeman ML, 2022. Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control. *J Infect Dis* 225, 1040-1049. PMID: 32603406; PMCID: PMC8922002

284. Rawlings SA, Torres F, Wells A, Lisco A, Fitzgerald W, Margolis L*, Gianella S, Vanpouille C, 2022. Effect of HIV suppression on the cytokine network in blood and seminal plasma. *AIDS* 36, 621-630. PMID: 34873090; PMCID: PMC8957508

285. Sass D, Fitzgerald W, Wolff BS, Torres I, Pagan-Mercado G, Armstrong TS, Miaskowski C, Margolis L*, Saligan L, Kober KM, 2022. Differences in Circulating Extracellular Vesicle and Soluble Cytokines in Older Versus Younger Breast Cancer Patients With Distinct Symptom Profiles. *Front Genet* 13, 869044. PMID: 35547250; PMCID: PMC9081604

286. Vanpouille C*, Wells A, Wilkin T, Mathad JS, Morris S, Margolis L*, Gianella S, 2022. Sex differences in cytokine profiles during suppressive antiretroviral therapy. *AIDS* 36, 1215-1222. PMID: 35608113 PMCID: PMC9283283
287. Bourgon N, Fitzgerald W*, Aschard H, Magny J-F, Guilleminot T, Julien Stirnemann J, Romero R, Ville Y, Margolis L*, Leruez-Ville M. Profile and concentration of cytokines fractions in amniotic fluid of fetuses infected with cytomegalovirus 2022 *Viruses* 2022 ;14(10):2145
288. Vanpouille C*, Wells A, Dan J, Rawlings SA, Little S, Fitzgerald W*, Margolis L*, Gianella S. HIV but not CMV replication alter blood cytokine network during early HIV infection in men *AIDS* 2022 36:621.
289. Carvajal Barriga EJ, Fitzgerald W*, Dimitriadis E, Margolis L*, Fields D. Sulfated endospermic nanocellulose crystals prevent the transmission of SARS-CoV-2 and HIV-1 (submitted to *Scientific Reports*) 290. Carvajal Barriga EJ, Fitzgerald W*, Dimitriadis E, Margolis L*, Fields D. Sulfated endospermic nanocellulose crystals prevent the transmission of SARS-CoV-2 and HIV-1 2023 *Scientific Reports* 13.1 : 6959.
290. Poveda E, Fitzgerald W*, Reglero C, Crespo M, Mariño A, Álvarez H, Valcarce N, Ruiz-Mateos E, Margolis L, Lederman MM, and Freeman ML. IL-18 and IL-3 in Extracellular Vesicles: Biomarkers for Durable Elite Control of HIV-1 2023 *J Infect Dis* Jun 15;227(12):1381-1385.

Extracellular vesicles and viruses: Are they close relatives?

Esther Nolte-*t* Hoen^a, Tom Cremer^a, Robert C. Gallo^{b,1}, and Leonid B. Margolis^c

Edited by Peter K. Vogt, The Scripps Research Institute, La Jolla, CA, and approved June 27, 2016 (received for review April 4, 2016)

Extracellular vesicles (EVs) released by various cells are small phospholipid membrane-enclosed entities that can carry miRNA. They are now central to research in many fields of biology because they seem to constitute a new system of cell-cell communication. Physical and chemical characteristics of many EVs, as well as their biogenesis pathways, resemble those of retroviruses. Moreover, EVs generated by virus-infected cells can incorporate viral proteins and fragments of viral RNA, being thus indistinguishable from defective (noninfectious) retroviruses. EVs, depending on the proteins and genetic material incorporated in them, play a significant role in viral infection, both facilitating and suppressing it. Deciphering the mechanisms of EV-cell interactions may facilitate the design of EVs that inhibit viral infection and can be used as vehicles for targeted drug delivery.

extracellular vesicles | exosomes | viruses | defective viruses | infection

The earth hath bubbles as the water has...
William Shakespeare, *Macbeth*
Act I, Scene 3

Cells in vivo and ex vivo release membrane vesicles. These extracellular vesicles (EVs) are 50- to 100-nm-sized lipid bilayer-enclosed entities containing proteins and RNA. Not long ago, EVs were considered to be "cellular dust" or garbage and did not attract much attention. However, it has recently been found that EVs can have important biological functions and that in both structural and functional aspects they resemble viruses. This resemblance becomes even more evident with EVs produced by cells productively infected with viruses. Such EVs contain viral proteins and parts of viral genetic material. In this article, we emphasize the similarity between EVs and viruses, in particular retroviruses. Moreover, we emphasize that in the specific case of virus-infected cells, it is almost impossible to distinguish EVs from (noninfectious) viruses and to separate them.

Let us start with definitions. Although EVs were discovered decades ago, EV research emerged as a separate field relatively recently and currently lacks sufficient practical nomenclature. In full analogy with viral biogenesis, some of these vesicles are generated inside cells and on release into the extracellular milieu are called "exosomes," whereas others pinch off from

the plasma membrane and are generally referred to as "microvesicles" (1). Most commonly, the general term EVs is used to refer to any membrane vesicle of a type that is released into the extracellular space. However, use of this general term not only masks the fact that EVs are highly heterogeneous in size, structure, and biogenesis but may also lead to apparent controversies when different studies deal with different entities but call them by the same name. The diversity of EVs may also underlie the large variety of roles ascribed to them in normal cell function and in pathologies (2).

In contrast to EVs, the definition of viruses developed by 20th century virologists was quite precise: both the *Encyclopedia Britannica* and the *Oxford English Dictionary* define virus as "an infectious agent of small size that can multiply only in living cells." EVs do not fall under this definition, because despite their resemblance to viruses in many aspects, they are fundamentally different, as they do not replicate. However, contemporary virology has distanced itself from this strict definition of virus by its wide use of the terms noninfectious and defective virus. Therefore, EVs generated by retrovirus-infected cells that carry viral proteins and even fragments of viral genomes essentially fall under the definition of noninfectious viruses.

Based on current knowledge, there are many aspects in which EVs resemble viruses, in particular

^aDepartment of Biochemistry and Cell Biology, Faculty Veterinary Medicine, Utrecht University, 3584 CM Utrecht, The Netherlands; ^bInstitute of Human Virology, University of Maryland, Baltimore, MD 21201; and ^cSection of Intercellular Interactions, Eunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892

Author contributions: E.N.-t.H., T.C., R.C.G., and L.B.M. analyzed data and wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.

See Core Concepts on page 9126.

¹To whom correspondence should be addressed. Email: rgallo@ihv.umaryland.edu.

retroviruses. First, although some EVs may be up to a micrometer in size, the majority of EVs are <300 nm, the size of a typical RNA virus. Like enveloped viruses, EVs are surrounded by a lipid membrane that also contains cell membrane proteins. Like many viruses, EVs are formed in the endosomal system or at the plasma membrane via defined biogenesis pathways, for example, involving the endosomal sorting complexes required for transport (ESCRT) machinery (1). Like viruses, EVs can bind to the plasma membranes of other cells, enter them either through fusion or endocytosis, and trigger specific reactions from these recipient cells (1). Finally, EVs carry genetic material, and this genetic material can change functions of the recipient cells (2, 3). Especially in the case of retroviruses, EVs generated in infected cells contain selected molecules of viral origin (4) and can be so similar to noninfectious defective viruses that have lost their ability to replicate that the difference between them becomes blurred. In other cases, EVs provide an "envelope" to nonenveloped viruses, e.g., hepatitis A, and these EV-encapsulated viruses can infect cells (5). Similarly, EV released by hepatitis C-infected cells can carry fully infectious viral genomes that in target cells generate new infectious viral particles (6).

In this Perspective, we suggest that in retrovirus infections a variety of diverse vesicles is released, such that on one extreme there are EVs consisting entirely of host cell components and on the other replication-capable viruses. In between these extremes are nonreplicating particles that can be considered both as defective viruses and as EVs containing various amounts of virus-specific molecules (Fig. 1).

Obviously, unlike true viruses, EVs that contain viral proteins and fragments of viral genomes do not cause outbreaks and epidemics. However, EVs can either directly interact with retroviruses or modulate host cells, thereby affecting the infection. Studies on other virus infections in which EVs were shown to affect antiviral immune responses [e.g., human herpesviruses, in particular Epstein-Barr virus (EBV)] or in which EVs were shown to entrap nonenveloped viruses (like hepatitis A virus and hepatitis E virus) have been reviewed elsewhere (7, 8).




Fig. 1. Structural similarities between EVs and virions. Cells infected with enveloped RNA (retro)viruses release vesicles containing a variety of host and viral factors. On one extreme, there are EVs consisting entirely of host cell components (blue), and on the other extreme there are infectious viruses surrounded by a host lipid bilayer and containing all of the virus-specific molecules (red) necessary for infectivity. In virus-infected cells, EVs incorporate fragments of the viral genome and viral (glyco)proteins. Moreover, virus infections modify the incorporation of host proteins and RNAs into EVs (light blue). Such infection-induced EVs and the so-called defective viruses and virus-like particles are intermediate entities, and the border between them seems not to exist.

EVs and Viruses Cross Paths in Biogenesis

Early discussions on relationships between EVs and viruses (9, 10) were largely based on the fact that both EVs and retroviruses use the cellular vesiculation machinery, which explained striking similarities between EVs and retroviruses in lipid composition (high cholesterol and glycosphingolipids) and protein content (tetraspanins, GPI proteins, and cytoplasmic proteins). Moreover, it was hypothesized that retroviruses exploit preexisting pathways for intracellular vesicle trafficking (The Trojan exosome hypothesis) (9) and could be regarded as "modified or mutated exosomes." Others disputed the idea, because in contrast to retroviruses, there was little evidence for an active role of EVs in functional modification of target cells via transport of bioactive proteins, lipids, and genetic material (10). Later, it was found that EVs do contain genetic material, mainly in the form of small RNAs (3,11,12). Besides the involvement of molecular mechanisms for sorting of specific proteins into EVs (13), numerous studies also indicate that the RNA content of EVs doesn't simply reflect the RNA content of the EV-producing cell. Although some RNAs may passively diffuse into EVs in the course of their biogenesis, active sorting of specific RNAs has been shown to depend on defined RNA-binding proteins (14). Moreover, EV-associated miRNAs and mRNAs have been found to be enriched in certain sorting motifs (14–16). Recent scientific breakthroughs have shown that EV-associated proteins, lipids, and genetic material can be functionally transferred to target cells (13, 17–19), strongly implying that EVs and (retro) viruses have in common not only structural but also some functional aspects. This similarity is a reflection of the similarity in biogenesis of EVs and viruses (Fig. 2).

"Mister Postman": What Do EVs and Viruses Deliver

Published data indicate that EVs share with viruses an important function that played a critical role in evolution, namely delivering bioactive material from one cell to another (7, 8, 20, 21). Specific combinations of lipids and proteins, in particular, tetraspanins (22), in the EV membrane can mediate specific targeting of vesicles to recipient cells and may determine the ability of vesicles to fuse with cellular membranes. These molecules, as well as genetic material and proteins enclosed in EVs (e.g., transcription factors and cytokines), constitute molecular signals that can affect the function of recipient cells. It is exactly this trait of being multicomponent transport units that EVs share with enveloped viruses. Below, we discuss further characteristics shared by EVs and viruses.

As suggested from the above, like viral envelope proteins, EV surface proteins can determine adhesion to the plasma membrane of specific target cells. The intercellular adhesion molecule 1 (ICAM 1), present in dendritic cell (DC)-derived EVs, for example, mediates EV recruitment by other DCs and activated T cells (23, 24). Interestingly, the combination of integrin proteins on tumor cell EVs was recently shown to determine their delivery to specific target organs, where these EVs prepare the site of metastasis (25). A number of cellular proteins are incorporated both in EVs and in virions. Tetraspanins, for example, are associated with EVs and have also been reported to be incorporated into retroviruses, in which these host proteins can play a role in infectivity (26). Other EV membrane proteins can act as ligands for receptors on the target cell plasma membrane. MHC class II-peptide complexes on DC-derived EVs, for example, can bind or target T-cell receptors (27). Besides proteins associated with the EV surface, lipids too can mediate signaling to target cells. Examples of EV-associated bioactive lipids include prostaglandin E2, which can play a role in tumor evasion and immune suppression, and lysophosphatidylcholine, which also affects membrane fusion




Fig. 2. Similarities between biogenesis of EVs and virions. EVs and enveloped retrovirus particles (e.g., HIV) are simultaneously released by infected cells and share pathways for biogenesis at the plasma membrane or at multivesicular bodies (MVBs). For example, proteins of the ESCRT complex and tetraspanins are involved in both virion and EV formation. Viral RNA (red) enters the cytoplasm, after which Gag-mediated virion assembly takes place in the MVB or at the plasma membrane. MVB can contain both virions and EVs and are released from the cell after fusion of the MVB with the plasma membrane through the action of Rab, SNARE, and SNAP proteins. Defective viruses are also formed but are noninfectious because of the lack of essential viral components. Whereas specific host proteins and RNAs (blue), such as CD63 and APOBEC3G, can be incorporated into virions, viral components (red) are also incorporated in the plethora of EV types released by the cells. These include fragments of the viral genome, viral miRNAs, and viral (glyco)proteins, such as Nef and Gag. This intertwining of their pathways for biogenesis blurs the distinction between virions and EVs.

and induces immune cell activation and chemotaxis (28, 29). EV surface proteins and lipids may also determine the ability of vesicles to fuse with cellular membranes, as they do in the case of viruses (30). Fusion of EVs with target cells allows EV-entrapped signaling molecules to exert effects on target cell functioning. These molecules include cytosolic proteins such as transcription factors and also cytokines such as IL-1 β that lack an N-terminal signal peptide and that are released via alternative secretion routes (31). Moreover, EVs can carry specific enzymes, such as metalloproteinases and leukotriene-synthesis enzymes (32). Interestingly, DNA polymerase can also be transported by EVs. Whereas early studies reported the association of a DNA polymerase that catalyzed ribonuclease-sensitive DNA synthesis (thus resembling viral reverse transcriptase but not proving its identity) with particulate structures in the cytoplasm (27), more recent data show that tumor EVs can display endogenous reverse transcriptase activity (28). This suggests that under certain conditions, reverse transcriptase can be incorporated into EVs.

Some data indicate that EVs, although less effectively than virions themselves, can transfer cytosolic proteins involved in antiviral responses, such as APOBEC3G and cGAMP (33–36), to recipient cells. However, the relative efficiency of virions and EVs in transferring these proteins may be dependent on cell type and environmental conditions.

In some cases, EVs can also deliver genetic material into target cells. After the initial discovery that EVs carry protein-encoding mRNAs and small noncoding RNAs involved in regulation of gene expression [microRNA (miRNA)] (3), several groups demonstrated alterations in target cell gene expression due to the transfer of such RNAs via EVs (2). Besides miRNAs, EVs also contain a large variety of other small noncoding RNAs, such as fragments of protein-coding regions and repeat sequences, which could also act as regulatory RNAs by influencing gene expression (11). Although the most of genetic material enclosed in virions encodes for viral proteins that are essential for virus replication, viruses and EVs unite in their capacity to transfer RNAs that can trigger pathogen recognition receptors (PRRs) in target cells. Fragments of the viral genome, as well as virus-encoded small RNAs, such as those encoded by EBV, and certain host cell miRNAs, have been shown to trigger target cell PRRs. Although triggering of the PRR system results in complex responses, in some cases it may induce an increased activation status of these cells (37–39). Most of the described EV-mediated effects on the function of other cells are restricted to *in vitro* systems or occur within the same organism. Whereas viruses transfer between organisms as well as from cell to cell within an organism, the functional transfer of EVs from one individual to the other, as has been suggested for semen- or mother's milk-derived EVs, has not been proven (12).

Mission (Almost) Impossible: Separation of Virions from EVs

Because EVs are produced by virtually all cells, probably every viral preparation is in fact a mixture of virions and EVs. To study their respective functions, it is necessary to separate EVs and virions. This is very difficult with some viruses, such as retroviruses, because both EVs and retroviruses are comparable in size (EVs ranging from 50 to 100 nm, virions being ~100 nm) and buoyant density (EVs: 1.13–1.18 g/L; most retroviruses: 1.16–1.18 g/L). Other membrane-derived materials may also have similar characteristics. Therefore, density gradients, which are often used to separate EVs from contaminating protein aggregates on the basis of differences in buoyant densities (40), are not always reliable for separation of EVs from viral particles. Similar technical hurdles were also experienced at the early stages of retrovirus research, when there were long-lasting disagreements and controversies regarding replication-incompetent oncoviral particles causing cancer and their dependence on competent helper viruses for propagation (41). In those early days, electron microscopists observed that ultracentrifuged viruses copelleted with other 100-nm-sized membrane-enclosed particles. In the case of mouse erythrocytosis, pseudorabies, and polio virus these particles were termed “defective interfering particles” (42). Such particles were found to be functionally active, e.g., in repressing virus infection or oncogenic transformation (43), and would nowadays perhaps be classified as “virus-induced EVs.” At this time, it was discovered that these noninfectious viruses could be separated from their infectious counterparts (helper virus) on the basis of their slower migration in density gradients (42). Interestingly, a similar method has more recently been reported for separation of EVs from HIV virions that are produced in HEK 293 T cells or present in the plasma of HIV-1-positive individuals (44, 45). Virus particles and EVs were separated on the basis of migration in velocity gradients and distinguished on the basis of the presence of p24 in virus particles and, for example, acetylcholinesterase and CD45 in EVs but not in HIV. Although it has been reported that in contrast to EVs, HIV particles do not incorporate CD45 (46) or acetylcholinesterase (44), it is not clear if this is universal, and of course, these markers may not be carried by all of EVs. The very criteria for purity of the isolated preparations become murky with the realization that the border between retrovirus virions, like HIV, and EVs is blurry (Fig. 1). This is obviously different in the case of EV-enclosed nonenveloped viruses, such as hepatitis A, which can be distinguished from nonenveloped virions using neutralizing antibodies. This approach cannot be applied to enveloped viruses, because viral envelope proteins to which neutralizing antibodies are formed can be incorporated into EVs. Unless more specifically defined, it is currently virtually impossible to specifically separate and identify EVs that carry viral proteins, host proteins, and viral genomic elements from enveloped viral particles that carry the same molecules. Nevertheless, high-throughput methods to analyze individual nano-sized particles may facilitate discrimination of different particles in the EV–virus continuum in the future. For example, recent developments in flow cytometry-based techniques have opened up the possibility to quantify and characterize particles 50–200 nm in size. Such developments include not only hardware adaptations in high-end flow cytometers to improve signal-to-noise ratios, but also optimized staining protocols for general labeling of EVs and the use of magnetic nanoparticles to screen the surface antigenic composition of EVs (47, 48).

To Be or Not to Be Infected: EVs in Pro- and Antiviral Strategies

In vivo, EVs can interact with viruses and with each other either directly or via modulation of host responses, thus participating in a “War and Peace” between viruses and host (49, 50). Some viruses

induce the infected cells to release modified EVs that facilitate infection by increasing the pool of susceptible target cells (e.g., by increasing the number of activated cells) or their susceptibility to viral infection or by serving as decoys that absorb antiviral antibodies, thereby compromising antiviral immunity. In contrast, EVs carrying viral proteins can also be beneficial to the host, for example, by providing dendritic cells with viral antigens to facilitate the initiation of adaptive immune responses. Hypothetically, the capacity of EVs to regulate the lifespan of permissive cells and to modify antiviral immune responses may give additional flexibility to the host in responding to viral infection. Thus, EVs formed during viral infection may play either pro- or counter-viral roles (Fig. 3). It is currently unknown whether the diverse functions ascribed to virus-induced EV may in part be explained by differences in the purity of EV populations used in various studies. A general understanding of parameters that determine the net effect of EVs on viral infections is therefore still lacking.

EVs Facilitate Viral Infection. Several HIV proteins and RNAs have been detected in EVs released from HIV-infected cells. One of the viral components released via EVs is the HIV transactivation response element (TAR) RNA (51). TAR is an RNA stem-loop structure located at the 5' ends of HIV-1 transcripts, which in infected cells can be bound by Tat, thereby facilitating recruitment of elongation factors and increased production of viral RNA (52). When transferred via EVs, TAR RNA can increase the population of susceptible target cells. Inside EV-targeted cells, the full-length TAR RNA is processed into miRNAs, which silence mRNA coding for Bcl-2 Interacting Protein. The consequent increase in resistance to apoptosis allows the cell to produce virus for a longer period, thereby facilitating HIV infection (51).

In addition, EVs released by HIV-infected cells selectively incorporate the HIV virulence factor Nef via interaction of the Nef secretion modification region with mortalin, a member of the Hsp70 family of chaperones involved in cellular protein trafficking (53). Delivery of the EV-associated Nef to T cells affects these cells in several ways. First, the transferred Nef may activate T cells, rendering them more susceptible to HIV infection (54). Second, EVs can deliver Nef to some of the bystander CD4⁺ T cells and induce cell senescence or death (55). This mechanism can contribute to the high level of T-cell deaths during the early stages of HIV infection, when viral load is still low (55). Finally, intercellular transfer of Nef by EVs may facilitate evasion of the humoral immune response by suppressing IgG2 and IgA production in B cells, as has also been shown for Nef transfer by HIV-infected macrophages to B cells via intercellular conduits (56). In *in vitro* systems, it has been shown that EVs can transfer the HIV coreceptors CCR5 and CXCR4 to other cells, thus making them prone to HIV infection (57, 58). This EV-mediated process may expand the spectra of HIV-infected cells, but it is yet unknown whether such a phenomenon plays an important role *in vivo*.

EVs Suppress Viral Infection. In *in vitro* experiments, it has been shown that T cells can produce EVs containing the HIV receptor CD4. These EVs can attach to viral particles, thereby decreasing the numbers of virions that would otherwise infect CD4⁺ T cells (59). However, HIV can counteract this by stimulating the incorporation of HIV-Nef into these EVs, leading to the inhibition of CD4 incorporation in EVs and a decreased effectiveness of the above-described host antiviral response (59).

Another EV-mediated host cell protection mechanism against HIV involves the EV-mediated transport of the host antiviral protein




Fig. 3. Proviral and antiviral effects of EVs released by retrovirus-infected cells. Retrovirus infection can lead to the release of modified EVs that either facilitate or suppress infection. Potential antiviral effects include (A) EV-mediated delivery of antiviral components, such as APOBEC3G, to increase resistance to infection; (B) spread of TLR ligands, such as viral RNA, via EVs to warn nonsusceptible neighboring cells of the presence of viral infection; and (C) provision of antigen presenting cells with viral antigen to facilitate the initiation of adaptive immune responses. Potential proviral effects include (D) inhibition of the neutralizing effect of EV, leading to decreased binding of EV to virions and an increase in the number of virions that may infect other cells; (E) EV-mediated delivery of viral components (e.g., Nef) that induce cell senescence or death of antiviral immune cells; (F) EV-mediated delivery of viral components that suppress the function of immune cells (e.g., Nef-induced down-regulation of antibody production by B cells); and (G) increase of the pool of virus-susceptible cells, e.g., by transference of coreceptors for virus binding to other cells.

APOBEC3G. This cytidine deaminase is usually incorporated into virions together with retroviral RNA and inhibits viral replication by creating G-to-A mutations in the transcribed viral DNA (60). The antiviral action of APOBEC3G is counteracted by the HIV-encoded protein Vif, which interferes with APOBEC3G incorporation into virions. Delivery of APOBEC3G without Vif via EVs can counteract the effect of Vif and thus increase resistance of EV-targeted cells to HIV infection (34). Similarly, recent data indicate that the second messenger cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) (induced by cGAMP synthase) is enclosed both in HIV particles and in EVs that are released from infected cells. Intercellular transfer of cGAMP, although accomplished more efficiently by viruses than by EV, triggers antiviral IFN responses in newly infected cells in a stimulator of interferon genes (STING)-dependent manner (35, 36).

EVs from virus-infected cells not only contain endogenous (mi) RNAs but have also been shown to be selectively enriched in viral RNAs (e.g., in the case of HCV-induced EVs) (38). The PRRs in EV-targeted cells may recognize such RNAs as pathogen-associated molecular patterns (PAMPs) and respond by triggering the innate antiviral response (38, 61). HIV-infected macrophages also release EV containing viral RNAs (viral miRNAs vmiR88 and -99) that trigger endosomal TLR8 and NF- κ B signaling in EV-targeted bystander macrophages (61). The subsequent production of proinflammatory cytokines (e.g., TNF α) contributes to the initiation of the immune response against HIV. Dissemination of viral RNA via EVs provides a strategy to warn nonsusceptible neighboring cells of the presence of viral infection. During HCV infection, for example, plasmacytoid DC

are targeted by viral RNA containing EVs and, as a result, initiate an inflammatory response (38). In addition, EVs containing host miRNA produced by virus-resistant cells can confer resistance to other cells. This has been demonstrated for trophoblasts, which are largely resistant to infection by various viruses, including HIV, probably contributing to in vivo fetus protection. EVs produced by these cells in vitro carry host miRNAs and deliver them to virus-susceptible cells, making them resistant to virus infection (62).

Conclusions: Prospects for EV Therapy

A growing body of evidence indicates that cells infected with enveloped or nonenveloped viruses release EVs that contain viral components. Here, we aimed to create awareness that virus preparations may never be pure but rather are contaminated with diverse subpopulations of EVs, and some of these EVs may be either indistinguishable from or very similar to so-called defective viruses. Because of their common biogenesis paths, viruses and EVs may be close relatives, although only the former can replicate in cells. Importantly, EVs generated by infected cells are not neutral, as they can either facilitate virus propagation or enhance the antiviral response. Understanding of the structure of EVs produced by infected cells, determining their cargo, and deciphering the fine mechanisms by which they affect viral infection are required not only for basic virology but also for translation into therapy. Below, we present three examples of potential utilizations of EVs in immunotherapy, vaccine development, and drug delivery:

(i) EVs with viral proteins can serve as decoys for antiviral antibodies by binding them, leaving infectious virions partially

undetected. Eliminating these EVs (e.g., with immunoabsorption based on their nonviral markers) may enhance antiviral immune responses. (ii) Understanding the roles of EVs in antiviral immune reactions may guide engineering of EVs that have strong antiviral properties. (iii) Knowledge of phenotypes and functions of EVs generated in response to viral inoculation can in the future be applied to improve virus vaccines by eliminating or adding defined subsets of EVs.

Targeted drug delivery is one of the most important and unresolved problems in pharmacology. By contrast, viruses are highly targeted: in the course of evolution they have acquired high specificity toward their cellular targets by incorporating specific binding proteins. Incorporation of such viral proteins onto the EV membrane may facilitate EV-mediated delivery of drugs to specific cells (63).

However, to achieve these goals several important questions need to be answered regarding the role of EVs in intercellular communication in the steady state and during viral infections:

- i) What are the exact mechanisms by which EVs affect viral infection at both cellular and systemic levels?
- ii) Can we use new technologies, some of which are described in this report, to obtain viral preparations free of contaminating EVs and, reciprocally, EV preparations produced by infected cells and

free of contaminating viruses? Only after we can obtain clean populations, can question # 1 be addressed experimentally.

- iii) How can we predict either in vitro or in vivo net biological activity when viruses and EVs are mixed?
- iv) Can we obtain EVs with specific (viral) surface proteins to target vesicles to particular cells and organs?
- v) Can we efficiently scale up the production of EVs so that we have sufficient quantities to test their in vivo effects and even perform clinical trials in the future?
- vi) Can we design and engineer EVs that block newly evolving viruses? Can we, for example, use EVs to block Zika viral infection developing in fetuses or to enhance antiviral activity to new influenza strains?

Answers to these questions will show whether the newly emerging field of extracellular vesicle research will become important for understanding fundamental mechanisms of virus infections and be translated into anti-viral therapeutic strategies.

Acknowledgments

E.N.-t.H. receives funding from the European Research Council (ERC) under the European Union's Seventh Framework Programme (FP/2007–2013)/ERC grant agreement 337581; the work of L.B.M. is funded by the National Institute of Child Health and Human Development/NIH Intramural Program; the work of R.C.G. is funded by the Gates Foundation, the National Institute of Allergy and Infectious Diseases, and the University of Maryland School of Medicine.

- 1 Colombo M, Raposo G, Théry C (2014) Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annu Rev Cell Dev Biol* 30:255–289.
- 2 Yáñez-Mó M, et al. (2015) Biological properties of extracellular vesicles and their physiological functions. *J Extracell Vesicles* 4:27066.
- 3 Valadi H, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 9(6):654–659.
- 4 Chahar HS, Bao X, Casola A (2015) Exosomes and their role in the life cycle and pathogenesis of RNA viruses. *Viruses* 7(6):3204–3225.
- 5 Feng Z, et al. (2013) A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. *Nature* 496(7445):367–371.
- 6 Bukong TN, Momen-Heravi F, Kodyk K, Bala S, Szabo G (2014) Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. *PLoS Pathog* 10(10):e1004424.
- 7 Meckes DG, Jr, Raab-Traub N (2011) Microvesicles and viral infection. *J Virol* 85(24):12844–12854.
- 8 Meckes DG, Jr (2015) Exosomal communication goes viral. *J Virol* 89(10):5200–5203.
- 9 Gould SJ, Booth AM, Hildreth JEK (2003) The Trojan exosome hypothesis. *Proc Natl Acad Sci USA* 100(19):10592–10597.
- 10 Pelchen-Matthews A, Raposo G, Marsh M (2004) Endosomes, exosomes and Trojan viruses. *Trends Microbiol* 12(7):310–316.
- 11 Nolte-t Hoen EN, et al. (2012) Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. *Nucleic Acids Res* 40(18):9272–9285.
- 12 Vojtech L, et al. (2014) Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions. *Nucleic Acids Res* 42(11):7290–7304.
- 13 Raposo G, Stoorvogel W (2013) Extracellular vesicles: Exosomes, microvesicles, and friends. *J Cell Biol* 200(4):373–383.
- 14 Villarroya-Beltri C, et al. (2013) Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. *Nat Commun* 4:2980.
- 15 Batagov AO, Kurochkin IV (2013) Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3'-untranslated regions. *Biol Direct* 8:12.
- 16 Koppers-Lalic D, et al. (2014) Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. *Cell Reports* 8(6):1649–1658.
- 17 Robbins PD, Morelli AE (2014) Regulation of immune responses by extracellular vesicles. *Nat Rev Immunol* 14(3):195–208.
- 18 Kowal J, Tkach M, Théry C (2014) Biogenesis and secretion of exosomes. *Curr Opin Cell Biol* 29:116–125.
- 19 Lo Cicero A, Stahl PD, Raposo G (2015) Extracellular vesicles shuffling intercellular messages: For good or for bad. *Curr Opin Cell Biol* 35:69–77.
- 20 Ridder K, et al. (2014) Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. *PLoS Biol* 12(6):e1001874.
- 21 Zomer A, et al. (2015) In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. *Cell* 161(5):1046–1057.
- 22 Andreu Z, Yáñez-Mó M (2014) Tetraspanins in extracellular vesicle formation and function. *Front Immunol* 5:442.
- 23 Segura E, et al. (2005) ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. *Blood* 106(1):216–223.
- 24 Nolte-t Hoen EN, Buschow SI, Anderton SM, Stoorvogel W, Wauben MH (2009) Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. *Blood* 113(9):1977–1981.
- 25 Hoshino A, et al. (2015) Tumour exosome integrins determine organotropic metastasis. *Nature* 527(7578):329–335.
- 26 Sato K, et al. (2008) Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins. *J Virol* 82(2):1021–1033.
- 27 Théry C, et al. (2002) Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. *Nat Immunol* 3(12):1156–1162.
- 28 Subra C, Laulagnier K, Perret B, Record M (2007) Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. *Biochimie* 89(2):205–212.
- 29 Chernomordik LV, Kozlov MM (2003) Protein-lipid interplay in fusion and fission of biological membranes. *Annu Rev Biochem* 72:175–207.
- 30 Dumas F, Preira P, Salomé L (2014) Membrane organization of virus and target cell plays a role in HIV entry. *Biochimie* 107(Pt A):22–27.
- 31 MacKenzie A, et al. (2001) Rapid secretion of interleukin-1beta by microvesicle shedding. *Immunity* 15(5):825–835.
- 32 Buzas EI, György B, Nagy G, Falus A, Gay S (2014) Emerging role of extracellular vesicles in inflammatory diseases. *Nat Rev Rheumatol* 10(6):356–364.
- 33 Harris RS, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. *Cell* 113(6):803–809.
- 34 Khatua AK, Taylor HE, Hildreth JEK, Popik W (2009) Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells. *J Virol* 83(2):512–521.

- 35 Bridgeman A, et al. (2015) Viruses transfer the antiviral second messenger cGAMP between cells. *Science* 349(6253):1228–1232.
- 36 Gentili M, et al. (2015) Transmission of innate immune signaling by packaging of cGAMP in viral particles. *Science* 349(6253):1232–1236.
- 37 Chen X, Liang H, Zhang J, Zen K, Zhang C-Y (2013) microRNAs are ligands of Toll-like receptors. *RNA* 19(6):737–739.
- 38 Dreux M, et al. (2012) Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. *Cell Host Microbe* 12(4):558–570.
- 39 Baglio SR, et al. (2016) Sensing of latent EBV infection through exosomal transfer of 5'pppRNA. *Proc Natl Acad Sci USA* 113(5):E587–E596.
- 40 Raposo G, et al. (1996) B lymphocytes secrete antigen-presenting vesicles. *J Exp Med* 183(3):1161–1172.
- 41 Maeda N, Fan H, Yoshikai Y (2008) Oncogenesis by retroviruses: Old and new paradigms. *Rev Med Virol* 18(6):387–405.
- 42 Eckner RJ, Hettrick KL (1977) Defective Friend spleen focus-forming virus: Interfering properties and isolation free from standard leukemia-inducing helper virus. *J Virol* 24(1):383–396.
- 43 Huang AS (1973) Defective interfering viruses. *Annu Rev Microbiol* 27:101–117.
- 44 Cantin R, Diou J, Bélanger D, Tremblay AM, Gilbert C (2008) Discrimination between exosomes and HIV-1: Purification of both vesicles from cell-free supernatants. *J Immunol Methods* 338(1–2):21–30.
- 45 Konadu KA, et al. (2016) Isolation of exosomes from the plasma of HIV-1 positive individuals. *J Vis Exp*, 10.3791/53495.
- 46 Esser MT, et al. (2001) Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: Implications for viral pathogenesis and immune regulation. *J Virol* 75(13):6173–6182.
- 47 Nolte-t Hoen EN, et al. (2012) Quantitative and qualitative flow cytometric analysis of nanosized cell-derived membrane vesicles. *Nanomedicine (Lond)* 8(5):712–720.
- 48 Arakelyan A, Ivanova O, Vasilieva E, Grivel J-C, Margolis L (2015) Antigenic composition of single nano-sized extracellular blood vesicles. *Nanomedicine (Lond)* 11(3):489–498.
- 49 Lisco A, Vanpouille C, Margolis L (2009) War and peace between microbes: HIV-1 interactions with coinfecting viruses. *Cell Host Microbe* 6(5):403–408.
- 50 Bhattarai N, McLinden JH, Xiang J, Kaufman TM, Stapleton JT (2015) Conserved motifs within hepatitis C virus envelope (E2) RNA and protein independently inhibit T cell activation. *PLoS Pathog* 11(9):e1005183.
- 51 Narayanan A, et al. (2013) Exosomes derived from HIV-1-infected cells contain trans-activation response element RNA. *J Biol Chem* 288(27):20014–20033.
- 52 He N, et al. (2010) HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. *Mol Cell* 38(3):428–438.
- 53 Shelton MN, Huang M-B, Ali SA, Powell MD, Bond VC (2012) Secretion modification region-derived peptide disrupts HIV-1 Nef's interaction with mortalin and blocks virus and Nef exosome release. *J Virol* 86(1):406–419.
- 54 Arenaccio C, et al. (2014) Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism. *J Virol* 88(19):11529–11539.
- 55 Lenassi M, et al. (2010) HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. *Traffic* 11(1):110–122.
- 56 Xu W, et al. (2009) HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. *Nat Immunol* 10(9):1008–1017.
- 57 Mack M, et al. (2000) Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection. *Nat Med* 6(7):769–775.
- 58 Rozmyslowicz T, et al. (2003) Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. *AIDS* 17(1):33–42.
- 59 de Carvalho JV, et al. (2014) Nef neutralizes the ability of exosomes from CD4+ T-cells to act as decoys during HIV-1 infection. *PLoS One* 9(11):e113691.
- 60 Soros VB, Yonemoto W, Greene WC (2007) Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. *PLoS Pathog* 3(2):e15.
- 61 Bernard MA, et al. (2014) Novel HIV-1 miRNAs stimulate TNF α release in human macrophages via TLR8 signaling pathway. *PLoS One* 9(9):e106006.
- 62 Delorme-Axford E, et al. (2013) Human placental trophoblasts confer viral resistance to recipient cells. *Proc Natl Acad Sci USA* 110(29):12048–12053.
- 63 György B, Hung ME, Breakefield XO, Leonard JN (2015) Therapeutic applications of extracellular vesicles: Clinical promise and open questions. *Annu Rev Pharmacol Toxicol* 55:439–464.